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A total of 140 single patient isolates of imipenem-resistant Pseudomonas aeruginosa 
f rom the N e w Territories East Cluster hospitals (NTEC), Hong Kong, collected during 
2001 - 2005 were tested for their susceptibility to 12 p-lactams and seven other antibiotics. 
Mechanisms of imipenem-resistance including production of P-lactamases, changes in 
membrane permeability, efflux and presence of integrons were investigated. More than 
50% of these isolates were resistant to ten and up to 19 antibiotics. Only one isolate each 
produced an OXA-3 and an OXA-10 p-lactamase. Twenty isolates were shown by an 
imipenem-EDTA disk method to produce metallo-beta-lactamase (MBL) but MBL genes 
including blamv, bla^ju and blasm could not detected in the isolates after amplification 
using primers specific for these genes. Crude (3-lactamase extracts from these isolates were 
unable to hydrolyze imipenem. 
Reduced expression of the oprD gene was detected in nine out of the 28 isolates 
that were selected for further study of the mechanisms of imipenem-resistance. 
Amplification followed by DNA sequence determination of the mexT gene, the negative 
regulator of oprD, showed that mutations were present in the mexT gene in 19 isolates. 
These mutations led to the mexT gene to become functional and so had down-regulated the 
expression of oprD. 
i 
A class 1 integron was detected in 94 of the 140 isolates studied. The blaoxA-3, 
blaoxA-io. aadAl, aadA2 and aadA6 genes were present in gene cassettes of the integrons. 
All 20 isolates shown to produce a MBL by a bioassay method harbored a class 1 integron 
but the 3, conserved region was not detected in 16 of these isolates. 
Imipenem-resistant P. aeruginosa isolates in the NTEC hospitals were usually 
multiply drug-resistant. Production of carbapenemase was not likely to contribute to 
imipenem-resistance. Loss of OprD protein, and overexpression of an efflux pump system 
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Chapter 1-Introduction 
1 Pseudomonas aeruginosa 
1.1 Microbiology 
Pseudomonas aeruginosa is the pseudomonad species that is most frequently 
recovered from clinical specimens. It is an oxidase-positive, non-fastidious Gram-
negative aerobe that derives its energy from oxidation rather than fermentation of glucose 
(Koneman et al” 1997) (Figure 1.1). 
1.1.1 Morphology , 
Most P. aeruginosa strains form characteristic blue-green colonies on nutrient 
agar due to the production of pyocyanin and fluorescein. These colonies are smooth and 
flat and most of them have a distinguishable fruity odor due to formation of o-
aminoacetophenone from tryptophan. P. aeruginosa grows well at to 3TC and is 
able to grow, albeit slower, at a lower or higher temperature; its ability to grow at 42°C 
distinguishes it from many other Pseudomonas species (Murray et al., 2005). 
The cells of P. aeruginosa are rod-shaped, measuring 0.5 - 0.8 [im by 1.5 - 3.0 |Lim. 
Most of the strains are motile by one or more polar flagellum. Clinical isolates usually 
have pili, which are antiphagocytic and aid in attachment to host cells for colonization. 
1.1.2 Identification 
1 
p. aeruginosa is identified by its inability to ferment lactose, a positive oxidase 
reaction, its ability to grow at 42°C and various other biochemical reactions (Murray et 
al, 2005). 
1.1.3 Pathogenesis and virulence 
P. aeruginosa produces many virulence factors. These include heat-stable 
hemolysin, phospholipase C, endotoxin, pigments (pyocyanin and fluorescein), proteases 
(elastase and alkaline protease), toxin A and exoenzyme S (Mandell et al, 2005; Murray 
et al, 2005). 
1.1.4 Host defenses 
Phagocytosis is an important host defense mechanism and together with 
opsonizing antibody, protecting the host against P. aeruginosa infections. Patients unable 
to produce antibodies due to various underlying diseases or immunosuppressive therapies 
usually have more serious P. aeruginosa infections (Mandell et al, 2005). 
1.1.5 Epidemiology 
P. aeruginosa commonly inhabits soil, water, and vegetation. It is a normal 
commensal of the skin, throat and stool of healthy persons. P. aeruginosa more 
frequently causes hospital-acquired infections than community-acquired infections. It is 
also resistant to some commonly-used disinfectants and is therefore a contaminant of 
disinfectants. It has also been isolated from respiratory equipment, food, sinks, taps and 
mops in hospitals. It is mainly acquired during invasive procedures or transmitted from 
patients to patients and from health care personnel to patients (Mandell et al, 2005). 
2 
1.1.6 Clinical manifestations 
P. aeruginosa is the third most common cause of nosocomial infections after 
Escherichia coli and Staphylococcus aureus (Liveimore and Pearson, 1996). Recent 
surveys have shown that P. aeruginosa is responsible for 10% - >20% of all nosocomial 
infections in the United States (NNIS, 1996). It can cause life-threatening infections such 
as bacteremia, pneumonia, etc in patients with altered host defenses, cystic fibrosis, 
wounds and burns or on chemotherapy (Mandell et al, 2005). Fatality rate can be as high 
as 50% among patients with these risk factors (Mandell et al, 2005). 
1.1.7 Treatment 
Although many antibiotics have modest antipseudomonal activity in vitro, only a 
minority of them show useful activity at therapeutically attainable concentrations. 
Carbenicillin is the first commercially available penicillin to show activity against P. 
aeruginosa. The other antipseudomonal penicillins include ticarcillin, azlocillin and 
piperacillin. Those cephalosporins that are active against P. aeruginosa include 
cefoperazone, cefsulodin, ceftazidime, cefpirome and cefepime. The monobactam 
aztreonam has also been reported to have antipseudomonal activity, however, the 
carbapenems such as imipenem and meropenem are the most active P-lactams against 
this organism (Cunha and Ristuccia, 1984). Newer carbapenems that have recently been 
developed include ertapanem and doripenem (Zhanel et al, 2005). 
The aminoglycosides are also active against P. aeruginosa. Despite of their 
nephrotoxicity and ototoxicity (Cunha and Ristuccia, 1984), life-threatening P. 
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aeruginosa infections are often treated with a combination of an aminoglycoside and a (3-
lactam agent that has excellent synergistic activities (Cunha and Ristuccia, 1984). 
Fluoroquinolones have also been used to treat pseudomonal infections. 
Ciprofloxacin is the most widely used fluoroquinolone in recent years. There is often an 
improvement in lung function with ciprofloxacin therapy in cystic fibrosis patients 
(Raeburn et al, 1987; Wolfson and Hooper，1989). 
2 p-Lactams 
The P-lactams are probably the most varied and widely used of all antimicrobial 
agents due to their low toxicity and high availability (Lorian, 1995). Benzylpenicillin is 
the first p-lactam that was discovered in 1928 but was put into clinical use in 1940. There 
are numerous natural and synthetic compounds described based upon the active structure 
of penicillin, the P-lactam ring (Figure 1.2). 
The penicillins and cephalosporins, which are based on 6-aminopenicillanic acid 
and 7-aminocephalosporanic acid, respectively, are the two classical P-lactam families. 
Penicillins such as benzylpenicillin are mainly active against Gram-positive bacteria 
while others such as ampicillin and carbenicillin are active against Gram-negative 
bacteria (Brumfitt et al., 1967; Lorian, 1995). Cephalosporins can be classified into 
generations according to their antibacterial spectrum. The first generation cephalosporins, 
such as cephalothin and cephradine, are mainly active against Gram-positive organisms. 
The second generation cephalosporins are more active against Gram-negative bacteria 
than the first generation cephalosporins but their activity against the Gram-positives 
decreases (Wise, 1992). The third generation cephalosporins are very active against most 
Gram-negative organisms but are much less active against Gram-positive organisms than 
the first or second generation cephalosporins. Most cephalosporins do not have good 
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antipseudomonal activity except the third generation cephalosporins, including cefpirome, 
cefoperazone, cefsulodin and ceftazidime, and the fourth generation cefepime of the so-
called antipseudomonal cephalosporins (Williams and Moosdeen, 1987; Duval et al, 
1993; Thornsberry et al, 1993). 
In addition, various nonclassical (3-lactams have been developed, including 
monobactams and carbapenems. Monobactams have been used extensively in the 
treatment of a variety of infections caused by Gram-negative pathogens, including P. 
aeruginosa. Its pharmacologic profile can be attributed to its unique chemical property. 
Monobactams have a single p-lactam ring structure, which differs substantially from 
those of the bicyclic-lactams, such as the penicillins and cephalosporins. Aztreonam is 
the only clinically used monobactam (Sykes et al, 1981; Sykes and Bonner, 1985). 
Carbapenems are P-lactams with the broadest spectrum of activity. Also, they are 
very stable to most (3-lactamases, more rapidly bactericidal than most other penicillins or 
cephalosporins and have been used to treat infections caused by most bacterial pathogens 
except mycobacteria, cell wall-deficient organisms, and a few infrequent non-fermenters 
and aeromonads. They are not hydrolyzed by extended-spectrum P-lactamases (ESBLs) 
and are active against hyperproducers of AmpC enzymes (Hashizume et al, 1984; 
Livermore and Woodford, 2000). Carbapenems differ from conventional penicillins in 
having no sulfur atom in their 5-membered ring, instead, they have a double bond 
between carbons 2 and 3 (Figure 1.3). The first carbapenem to be used clinically is 
imipenem in the 1980s (Walsh et al., 2005). Other carbapenems include meropenem, 
ertapenem and doripenem (Zhanel et al, 2007), with ertapenem having the most limited 
spectrum of activity because it is inactive against P. aeruginosa and Enterococcus sp 
(Wexler, 2004). 
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p-Lactamase inhibitors are p-lactams but they do not have any antimicrobial 
properties. They are usually used in combination with those p-lactams that are sensitive 
to p-lactamases. Clinically-used (3-lactamase inhibitors include clavulanic acid that is 
combined with amoxicillin and ticarcillin and the penicillanic acid sulfone sulbactam and 
tazobactam, the former combined with ampicillin and the latter with piperacillin 
(Rolinson, 1991). 
2.1 Mode of action of p-lactams 
p-Lactams are bactericidal since they inhibit synthesis of peptidoglycan (Tipper 
and Strominger, 1965; Waxman and Strominger, 1983), the major polymer of the 
bacterial cell wall. Peptidoglycan plays an essential role in bacteria by maintaining the 
cell shape and protects against osmotic forces. In Gram-positive organisms, the 
peptidoglycan forms a thick layer external to the cytoplasmic membrane while in Gram-
negative bacteria and mycobacteria, it forms a thin layer between the outer and 
cytoplasmic membrane (Nikaido, 1994). 
P-Lactams have an affinity for penicillin binding proteins (PBPs), which are the 
enzymes responsible for cell wall synthesis and thus are targets of p-lactams. Binding of 
p-lactams to a cell causes it to swell and finally to burst (Spratt 1975; Frere and Joris, 
1985). 
2.2 p-Lactam-resistance 
P-Lactams are the most widely used antimicrobial agents clinically. However, 
emerging p-lactam-resistant strains are found in many parts of the world. p-Lactam-
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resistance results in treatment failure and therefore is a global life-threatening health 
problem. 
2.3 Resistance mechanisms 
Mechanisms of P-lactam-resistance can be either acquired or intrinsic. The 
mechanisms primarily include alteration of bacterial target, reduction of the uptake of 
antibiotics into bacterial cells, production of enzymes that degrade or modify the 
antibiotics, and presence of efflux pump systems. 
2.3.1 Changes in PBPs 
An important mechanism of resistance to P-lactams is the alteration of PBPs. The 
resistant strains produce another PBP that has decreased affinity to the antibiotics in order 
to take up the function of the original protein and to escape the action of the antibiotics. 
Alterations in PBPs are an important mechanism of P-lactam-resistance of Gram-positive 
bacteria, such as S. aureus, Streptococcus pneumoniae and Gram-negative bacteria, such 
as Neisseria gonorrhoeae and Pseudomonas sp (Godfrey et al, 1981; Spratt 1988; Spratt, 
1994). 
The change in PBPs may be due to acquisition of a single foreign gene, such as 
the mecA gene that codes for a variant of PBP 2, designated PBP 2a, in S. aureus. Since 
PBP 2a has low affinity for all p-lactams, production of PBP 2a leads to the development 
of resistance to all P-lactams in S. aureus (Ubukata et al, 1989). In contrast, S. 
pneumoniae takes up segments of genes that code for PBPs released from dead p-lactam-
resistant bacteria and then inserts them into its own PBP genes to form "mosaic genes". 
These "mosaic genes" code for PBPs that have very low affinity to p-lactams thus 
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resulting in P-lactam-resistance. S. pneumoniae strains that are resistant to high 
concentrations of penicillin have changes in four PBPs while those resistant to low 
concentrations have changes in only three (Jabes et al, 1989). 
2.3.2 Impermeability 
Hydrophilic antimicrobial agents enter into Gram-negative bacteria by diffusion 
through channels formed by "porin" proteins that are present in the outer membrane 
(Nikaido, 1985; Nikaido and Vaara 1985). Alterations in porin gene expression that lead 
to fewer porins or porins of a different size or structure decrease the amount of an 
antibiotic that can enter into the bacterial cell. Since different classes of antibiotics may 
use the same porin to enter the cell, alterations in outer membrane porins that affect 
permeability to one drug may affect permeability to a number of unrelated antimicrobial 
agents. Loss of porins is one of the mechanisms of p-lactam-resistance in Gram-negative 
organisms, including E. coli, Proteus sp, P. aeruginosa, Acinetobacter baumannii, 
Serratia marcescens, and Klebsiella pneumoniae (Raimondi et al, 1995; Clarke et al, 
2003; Quale et al, 2003). In E. coli, mutations in outer membrane protein encoding genes 
ompF and ompC lead to structural alterations in the protein and are associated with P-
lactam resistance (Yoshimura and Nikaido, 1985). These mechanisms render bacteria to 
become resistant to high concentrations of antibiotics (Martinez-Martinez et al., 1996). 
2.3.3 p-Lactamases 
3-Lactamases are the major defence of Gram-negative bacteria against (3-lactams. 
They disrupt the amide bond of the P-lactam ring thus rendering the antimicrobial 
inactive (Majiduddin et al, 2002; Helfand et al, 2003). No sooner has one new P-lactam 
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been developed and put into clinical use one or more bacterial species start to produce a 
P-lactamase that can hydrolyze it (Medeiros, 1997). As a result there are as many P-
lactamases as there as new P-lactams that have been developed to specifically resist 
hydrolysis by p-lactamases. Thus, there is a (3-lactamase that can hydrolyze each class of 
3-lactams. 
Shah and colleagues reported in 2004 that there are >340 known P-lactamases 
(Shah et al, 2004) and there are certainly many more p-lactamases reported since then. 
These P-lactamases are encoded by genes that can be borne on a transposon or plasmid or 
on the chromosome. Chromosomal p-lactamases show some sequence homology with 
PBPs and are thus thought to have evolved from them (Ghuysen, 1991). The rapid spread 
of P-lactamases among clinical isolates is due to encoding genes being borne on a 
plasmid or transposon (Bradford, 2001). The TEM-1 enzyme, the first pi asm id-mediated 
p-lactamase discovered, was reported in the 1960s' in Greece (Medeiros, 1984). Since 
then, it and its variants develop and spread rapidly worldwide and are the most common 
plasmid-mediated p-lactamases produced by bacteria within the family 
Enterobacteriaceae (Philippon et al, 1994). 
3-Lactamases can be classified into four molecular classes based on sequence 
(classes A to D) or into 11 functional groups based on substrate profiles (the substrates 
they can hydrolyse) and inhibitor profiles (the inhibitors that can inhibit their activities) 
(Ambler et al, 1991; Bush et al, 1995). 
Class A p-lactamases include both chromosomal and plasmid-mediated enzymes 
and are inhibited by clavulanic acid. Class B P-lactamases, also known as metallo-
enzymes (MBLs), require zinc for activity, are resistant to classical P-lactamase 
inhibitors but susceptible to EDTA. Class C enzymes, also known as AmpC enzymes, are 
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chromosomal cephalosporinases that are resistant to inhibition by clavulanic acid and are 
typically produced by Enterobacteria. AmpC p-lactamases are mainly found in K. 
pneumoniae and E. coli worldwide (Philippon et al, 2002). Class D enzymes are also 
known as oxacillinases since they hydrolyze oxacillin more effectively than 
benzylpenicillin. Classes A, C and D P-lactamases have serine as their active site (Bush 
et al, 1995). P-Lactamases of classes A and D are the most common. Class A enzymes 
such as TEM-type, SHV-type and CTX-M-type are commonly produced by Gram-
negative bacteria such as E. coli while class D enzymes such as OXA-type are frequently 
produced by P. aeruginosa (Medeiros et al, 1984). 
2.3.3.1 Extended spectrum p-lactamases 
Extended spectrum p-lactamase are co-called since they can hydrolyze the 
extended-spectrum P-lactams that include the third generation cephalosporins and 
monobactams. They are mainly derivatives of TEM-1 and SHV-1 enzymes due to 
presence of point mutations in the encoding genes, which are often located on 
transferable plasmids (Jacoby and Medeiros, 1991; Bush et al, 1995) 
(http ://www. lahey.org/studies). 
More than 130 TEM-type ESBLs have been identified. TEM-10, TEM-12, and 
TEM-26 are among the most common in North and South America (Paterson et al, 2003). 
Another common ESBLs are the SHV-type enzymes. More than 50 SHV-type enzymes 
have been reported and are mainly detected in resistant clinical isolates in Europe and 
America (Yuan et al, 1998; Paterson et al, 2003). The SHV-5 and SHV-12 are the most 
common members among the SHV family (Paterson et al, 2003). Both TEM-type and 
SHV-type ESBLs are most commonly found in K. pneumoniae and E. coli but they are 
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also found in many other Enterobacteriaceae, such as Proteus sp and Providencia sp 
(Livermore 1995; Rasheed et al, 1997; Bonnet et al, 1999; Marchandin et al, 1999). 
ESBLs, such as TEM-42 and SHV-2a p-lactamases, have also been found in P. 
aeruginosa isolates (Mugnier et al, 1996; Naas et al, 1999). 
The most common group of ESBLs not belonging to the TEM or SHV families 
was termed CTX-M, which has a greater activity to hydrolyze cefotaxime. More than 40 
CTX-M enzymes have been described. They have been found in strains of Salmonella 
enterica serovar Typhimurium and E. coli, but have also been described in other species 
of Enterobacteriaceae (Bonnet, 2004). Strains with CTX-M-type p-lactamases have been 
isolated from many parts of the world and have often been associated with focal 
outbreaks in Eastern Europe (Gazouli et al, 1998; Gniadkowski et al, 1998), South 
America (Bradford et al, 1998), and Japan (Ma et al, 1998). 
The OXA-type enzymes are another growing family of ESBLs. Unlike most of 
the other ESBLs, which have been found in E. coli, K. pneumoniae, and other 
Enterobacteriaceae, the OXA-type ESBLs are mainly produced by P. aeruginosa (Danel 
et al, 1997; Hall et al, 1993; Poirel et al., 2001a). Currently, more than 120 different 
variants of OXA-type ESBL have been identified (Walther-Rasmussen and Hoiby, 2006). 
2.3.3.2 Carbapenemases 
Carbapenemases are P-lactamases of classes A, B or D that significantly 
hydrolyze imipenem and / or meropenem and are one of the mechanisms of carbapenem-
resistance. The number of carbapenamases has increased over the last few years and at 
least seven types have been reported (Walsh et al, 2005). These P-lactamases can be 
either chromosomally- or plasmid-mediated. Bacterial species that produce chromosomal 
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carbapenemases are usually environmental organisms such as Flavobacterium (Bellais et 
al, 1999) and Chryseobacterium sp (Bellais et al, 2000), Aeromonas hy drop hi I a 
(Massidda et al, 1991), Legionella gormanii (Boschi et al, 2000) and Janthinobacterium 
lividum (Rossolini et al, 2001). 
A few class A carbapenamases have been reported in rare enterobacterial species. 
These carbapenamases may not mediate high-level imipenem-resistance or be inhibited 
by clavulanic acid (Poirel and Nordmann, 2002). NMC-A is the first class A 
carbapenemase identified in France in 1990 in an Enterobacter cloacae clinical isolate 
(Nordmann et al, 1993). Other class A carbapenemases identified so far include SME-1 
to SME-3 (Yang et al., 1990), IMI-1 (Rasmussen et al, 1996), KPC-1 (Yigit et al, 2001) 
and GES-2 (Poirel et al, 2001b). 
The class B metallo-P-lactamases (MBL) are the most common carbapenamases. 
The encoding genes are transferable and have been detected in a variety of Gram-
negative organisms, especially P. aeruginosa and A. baumanni (Walsh et al, 2005). In 
Korea, P. aeruginosa producing MBLs accounts for nearly 20% of all nosocomial 
isolates (Lee et al, 2003). MBLs have a very broad substrate profile that includes 
expanded-spectrum cephalosporins (such as cefotaxime, ceftazidime, and cefepime) and 
carbapenems but not the monobactams (Haruta et al, 2000). 
The IMP-type carbapenemases is the most common group of MBLs. IMP-1, the 
first carbapenemase, was identified in a S. marcescens strain isolated in 1991 in Japan 
(Osano et al., 1994). More than 18 blajMP genes coding for different IMP-type (3-
lactamases have so far been identified in Gram-negative bacteria in many places 
(Livermore and Woodford, 2000) and are usually present as gene cassettes in class 1 
integrons. However, IMP-type MBLs predominate in Asian countries, especially in Japan 
and Korea. The lMP-1, IMP-2 and IMP-10 have been reported in P. aeruginosa isolates 
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from Japan (Watanabe et al, 1991; Shibata et al., 2003), IMP-1 in P. aeruginosa and A. 
baumanni isolates in Korea (Lee et al, 2003), IMP-4 in Acinetobacter isolates in Hong 
Kong (Chu et al, 2001) and in Citrobacter youngae isolates in China (Hawkey et al, 
2001). IMP-type MBLs isolated outside of Asia include IMP-5 in an A. baumannii isolate 
from Portugal (Da Silva et al, 2001), and IMP-7 in a P. aeruginosa isolate in Canada 
(Gibb et al, 2002). 
The VIM-type enzymes are another group of MBLs encoded by transferable 
genes. VIM-1 is the first of the group of enzymes to be detected in a P. aeruginosa strain 
isolated in 1997 in Italy (Lauretti et al, 1999). Although the VIM-type enzymes share 
less than 30% amino acid identity with the IMP enzymes, they possess the same broad-
spectrum substrate profile that includes all P-lactams except aztreonam (Senda et al, 
1996a). Most blamu genes are also present as gene cassettes in class 1 integrons. More 
than 11 VIM variants have been described so far. They are commonly found in Europe, 
for example VIM-1 and VIM-2 in P. aeruginosa isolates in Italy (Lauretti et al, 1999; 
Pallecchi et al., 2001), VIM-4 in P. aeruginosa isolates in Greece (Pournaras et al., 2002) 
and VIM-5 in P. aeruginosa solates in Turkey (Bahar et al., 2004). However, there seems 
to be a worldwide spread of VIM-type enzymes since VIM-7 have been detected in P. 
aeruginosa isolates in the United States (Toleman et al, 2002), VIM-3 in R aeruginosa 
isolates in Taiwan (Yan et al, 2001) and VIM-2 in S. marcescens isolates in Korea (Yum 
et al, 2002). 
SPM-type and GIM-type enzymes are less common MBLs. The SPM-type 
enzyme, first described in Brazil from a P. aeruginosa isolate in 1997, seems to be 
limited to this country (Toleman et al, 2002). GIM-1 was recovered from P. aeruginosa 
isolates from Germany (Castanheira et al, 2004). Other GIM variants are rarely reported. 
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The number of oxacillinases (OXA), class D P-lactamases that have carbapenem-
hydrolysing properties, have increased considerably in recent years. There are at least 
seven carbapenem-hydrolyzing OXA enzymes (Walther-Rasmussen and Hoiby, 2006). 
Of these, OXA-23 in A. baumannii isolates has been reported from China (Yu et al, 
2004), OXA-25 in A. baumannii isolates from Spain (Afzal-Shah et al, 2001) and OXA-
50a in P. aeruginosa isolates from South Africa (Girlich et al, 2004). These OXA-type 
carbapenemases are mainly found in these two species. The genes coding for the OXA-
type carbapenemases are not integrated into integrons as gene cassettes but are present on 
the chromosome. Most OXA-type carbapenemases have weak carbapenemase activity 
only. Carbapenem-resistance in OXA-type carbapenemase-producing strains may be a 
result of a combination of other resistance mechanisms such as lack of specific porins and 
overexpression of efflux pump encoding genes (Walther-Rasmussen and Hoiby, 2006). 
2.3.4 Efflux pump systems 
To decrease the amount of an antimicrobial that accumulates within a cell by 
efflux pump systems that actively pumps out antibiotic molecules, these systems are 
responsible for antibiotic resistance. Efflux pump systems actually play an important role 
in the physiological function since they also pump out numerous dyes, detergents, 
inhibitors, disinfectants and substances that are harmful to the microorganism. Efflux is a 
common mechanism of antibiotic resistance since it has been demonstrated in many 
antibiotic resistant bacteria (Kohler et al, 1999). 
Antibiotic efflux systems can be classified into five major groups according to the 
structure of the cytoplasmic membrane transporter proteins: the resistance-nodulation-
division (RND) family, the major facilitator (MF) superfamily, the multidrug and toxic 
compound extrusion (MATE) family, the ATP-binding cassette (ABC) family, and the 
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small multidrug resistance (SMR) family (Li and Nikaido, 2004; Poole 2004). 
Transporters of the RND family are antibiotic efflux pumps that are responsible for 
antibiotic resistance and are the most common among Gram-negative bacteria. These 
efflux pump proteins are highly homologous and are arranged in three “layers” with 
drug-proton antiporter of the RND family (MexB, MexD, MexF and MexY) in the 
cytoplasmic membrane; a membrane fusion protein (MFP) (MexA, MexC, MexE and 
MexX) in the periplasmic space and a channel-forming protein (also known as outer 
membrane factor (OMF) (OprM, OprJ and OprN) in the outer membrane, a channel is 
thus formed connecting the inner and outer membranes. There are four efflux systems 
that are capable of pumping out multiple drugs including (3-lactams. They are MexA-
MexB-OprM, MexC-MexD-OprJ, MexE-MexF-OprN and MexX-MexY. These pumps 
share a similar genetic organization (Figure 1.5) but differ in substrate specificity and 
regulation (Poole 2000). 
The MexA-MexB-OprM (MexAB-OprM) system is constitutively expressed even 
in wild-type strains and is therefore responsible for intrinsic resistance. Expression of the 
mexAB-oprM operon is repressed by a gene known as mexR. Mutation(s) in the mexR 
gene can lead to overexpression of the MexAB-OprM system (Poole et al., 1996). 
Substrates of this efflux system other than P-lactams (including carbenicillin, piperacillin, 
ceftazidime, cefepime and aztreonam) include fluoroquinolones, tetracycline and 
chloramphenicol (Li et al., 1994; Yoneyama, et al., 1997; Saito et al., 1999; Masuda et 
aL, 2000b; Srikumar et al., 2000). 
In contrast to the MexAB-OprM system, the MexC-MexD-OprJ (MexCD-OprJ) 
and MexE-MexF-OprN (MexEF-OprN) systems are not expressed in wild-type strains. 
The MexCD-OprJ efflux system is regulated by the NfxB repressor (Okazaki and Hirai, 
1992). Mutations in the NfxB encoding gene inactivate the NfxB repressor resulting in 
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overexpression of the MexCD-OprJ system and leading to resistance to fluoroquinolones 
and P-lactams that include piperacillin, cefepime and meropenem (Poole, 2001). MexEF-
OprN is positively regulated by mexT since mutations in this gene can lead to 
overexpression of the mexEF-oprN operon, resulting in resistance to fluoroquinolones, 
trimethoprim, and chloramphenicol (Kohler et al., 1997; Kohler et al., 1999; Maseda et 
al., 2000). 
The MexX-MexY (MexXY) system utilizes OprM since it does not have its own 
outer membrane protein (Masuda et al., 2000a; Chuanchuen et al, 2001). Its expression 
can be induced by tetracycline or aminoglycosides (Aires et al., 1999; Mine et al, 1999; 
Masuda et al., 2000a). The substrates of the MexXY-OprM system include 
fluoroquinolones, aminoglycosides, and P-lactams that include piperacillin, cefepime, 
and meropenem (Aires et al, 1999; Mine et al., 1999; Masuda et aL, 2000a; Sobel et al., 
2003; Wolter et al., 2004). The expression of mexXY is repressed by the mexZ gene since 
mutation(s) in mexZ lead to overexpression of this system (Vogne et al., 2004). 
In contrast to most P-lactams, imipenem is not a substrate of these multidrug 
efflux systems since it has strong hydrophilic side-chains (Li et al., 1994; Kohler et al., 
1999; Pai et al, 2001). Trias and Nikaido (1990) showed by a liposome swelling assay 
that imipenem penetrates specifically through the outer membrane protein OprD. 
Increased efflux pump system expression does not affect imipenem susceptibility since 
influx of the drug through OprD membrane protein is more rapid than extrusion via 
efflux systems (Trias and Nikaido, 1990). 
2.4 Mechanisms of imipenem-resistance in P. aeruginosa 
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The major mechanisms leading to imipenem-resistance in P. aeruginosa include 
production of carbapenem-hydrolyzing enzymes, loss of an outer membrane protein, 
overexperession of efflux pump systems and hyperproduction of AmpC-p-lactamase 
(Livermore 1992; Livermore 2000). 
. There are five porins in P. aeruginosa, OprC, OprD, OprF and OprE (Gotoh et al., 
1989). OprD is a 46-kDa outer membrane protein that forms small base-specific pores 
through which basic amino acids and antibiotics such as carbapenems enter into the cell. 
However, penicillins, cephalosporins, monobactams and other P-lactams cannot pass 
through these pores (Huang and Hancock, 1993). 
At least two types of imipenem-resistant mutants have been described regarding 
the outer membrane protein. The major type involves the loss of OprD. Genetic anaylsis 
of laboratory-derived mutants has shown that the loss of OprD expression is due to 
deletions in the oprD coding region and the upstream promoter region (Yoneyama and 
Nakae, 1993). Such mutants are resistant only to carbapenems (Lynch et al, 1987). 
An alternative mechanism is the decreased production of OprD protein resulting 
in resistance to both imipenem and other unrelated classes of antibiotics (Cambau et al, 
1995; Fukuda et al, 1995). The nfxC mutants, also known as norfloxacin mutants, show 
cross-resistance to fluoroquinolones and imipenem and have reduced expression of OprD 
(Masuda et al, 1995) as well as overexpression of the MexEF-OprN efflux pump sytem 
resulting in overproduction of the membrane fusion protein MexE, cytoplasmic 
membrane protein MexF, and the outer membrane protein OprN (Kohler et al., 1997). 
Although imipenem cannot be pumped out by the MexEF-OprN pump, overexpression of 
the mexEF-oprN is linked to decreased amounts of the OprD protein (Fukuda et al, 1990; 
Masuda et al, 1995). 
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The MexEF-OprN system is positively regulated by MexT which is also a 
negative regulator for OprD protein expression. Overexpression of mexEF-oprN and 
decreased expression of oprD in P. aeruginosa are a result of a mutated mexT (Kohler et 
al., 1999; Ochs et al, 1999; Maseda et al, 2004). Sobel and colleagues (2005) showed 
that disruption of a gene immediately upstream of mexT in a clinical isolate of P. 
aeruginosa enhances mexEF-oprN expression and decreases OprD production, resulting 
in the organism becoming resistant to multiple drugs (Figure 1.5). 
AmpC p-lactamase is produced constitutively at low levels by most enterobacteria 
and P. aeruginosa (Bush et al, 1995; Livermore 1995), but its production is induced by 
certain P-lactams such as cefoxitin and imipenem (Giwercman et al, 1990; Wu and 
Livermore, 1990). The AmpC p-lactamase can also be overproduced due to mutations in 
the encoding genes resulting in resistance to broad-spectrum cephalosporins and 
monobactams (Sanders and Sanders Jr，1987). Mutations in ampG, the gene coding for a 
permease that allows entry of muropeptides into the cytoplasm from the periplasmic 
space (Korfmann and Sanders, 1989; Lindquist et al., 1993; Hanson and Sanders, 1999), 
ampD, the gene coding for an amidase that cleaves the muropeptides that enter the 
cytoplasm (Lindberg et al, 1987; Lindquist and Normark, 1987; Jacobs et al., 1995; 
Hanson and Sanders, 1999) and ampR, the gene coding for a protein that regulates ampC 
gene expression are responsible for hyperproduction of AmpC P-lactamase (Lindberg et 
al, 1987; Kuga et al, 2000). Although imipenem is relatively stable to AmpC hydrolysis, 
hyperproduction of AmpC p-lactamase is commonly found in imipenem-resistant isolates 
(Quale et al, 2006). However, other mechanisms responsible for imipenem-resistance are 
also present in these isolates (Livermore 1995; Yang et al, 1995; Quale et al, 2006). 
2.4.1 Prevalence of imipenem-resistant P. aeruginosa isolates 
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Although imipenem is active against many Gram-negative bacteria and has been 
used successfully to treat infections caused by these bacteria, strains resistant to 
imipenem have increasingly been reported throughout the world. 
In South Africa, the prevalence of imipenem-resistance is alarmingly high at 42% 
in P. aeruginosa and 32% in A. baumannii (Brink et al., 2007). 
According to a surveillance study of bacterial pathogens in intensive care units in 
Europe and North America performed during 2000-2002, imipenem-resistance is mainly 
found among Acintobacter spp and P. aeruginosa isolates while other Gram-negative 
bacteria are usually susceptible to imipenem (Jones et al, 2004). The percentage of 
imipenem-resistant P。aeruginosa isolates ranges from 18% in Canada to 28% in Italy 
while that in Acintobacter spp ranges from 2% in Canada to 19% in Italy (Jones et al, 
2004). 
Imipenem-resistance is also high among P. aeruginosa and Acinetohacter spp 
isolates from Asian countries (Wang et al, 2003; Sasaki et al., 2004; Lee et cd., 2006). In 
China, there has been a decrease in the susceptibility of P. aeruginosa isolates to 
imipenem from 88% in 1994 to 77% in 2001 (Wang et al, 2003). In Korea, 24% of P. 
aeruginosa isolates and 17% of Acinetohacter sp. isolates are resistant to imipenem while 
the corresponding figure for most of the other Gram-negative bacteria is <3% (Lee et al, 
2006). In Japan, 22% of P. aeruginosa isolates recovered from patients in surgical wards 
from different regional hospitals are resistant to imipenem (Sasaki et al., 2004). 
Imipenem-resistance is also a serious problem in Britain being found in a variety 
of Gram-negative bacteria other than P. aeruginosa and Acintobacter spp. During 2001-
2002, 3% of E. coli isolates, 6% o^ Klebsiella sp isolates, 8% of M. morganii isolates, 4% 
of Serratia sp isolates, 7% of P. aeruginosa isolates, 30% of Citrobacter sp isolates, 35% 
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of Enterohacter sp isolates and all of S. maltophilia isolates were resistant to imipenem 
(Reynolds et al, 2004). 
3 Integrons 
3.1 Structure and classification 
Integrons are elements harboring genes which determine a recombination system 
that are site-specific. This recombination system enables an integron to recognize and 
capture genes that are usually found in cassettes known as gene cassettes. An integron 
contains the gene coding for the enzyme integrase {int) that excises and then integrates a 
gene cassette in the integron, a promoter that governs the expression of the integron, and 
a gene for the recombination site (atti) at which gene cassettes are recognized and 
inserted (Figure 1.6). The gene cassettes are so-called foreign genetic elements which are 
integrated and then become part of the integron. Integrons can be present on transposons, 
plasmids or chromosomes but they themselves are not mobile (Hall and Collis, 1995). 
There are two different groups of integrons, the resistance integrons and the 
super-integrons. The resistance integrons are so-called since the cassettes carry genes that 
code for resistance to antibiotics and/or disinfectants. They can be present on the 
chromosome or on plasmids. There are three classes of resistance integrons, namely 1, 2 
and 3. Super-integrons are larger than resistance integrons, have only been found on the 
chromosome, and harbor gene cassettes coding for different functions. There are thus 
four classes of integrons with the super-integrons belonging to class 4. The integrons are 
classified according to the homology of the integrase which, in each of the classes, is of 
40% - 60% amino acid identity (Carattoli 2001). 
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3.1.1 Class 1 integrons 
The class 1 integron is the most common integron since it is found in many 
bacterial species. An integron contains two conserved segments, the 5,-conserved 
segment (5’-CS) and the 3'-conserved segment (3,-CS). The 5，-CS consists of the inti 
gene, the promoter, and the attl site while the 3 '-CS contains a qacEAl gene that codes 
for resistance to quaternary ammonium compounds and a sull gene that codes for 
resistance to sulphonamides (Stokes and Hall, 1989; Recchia and Hall, 1995). 
A gene cassette is made up of a gene and a recombination site, the 59-base 
element or attC, for integration into an integron. The 59-base elements are variable in 
length and therefore not conserved (Hall et al, 1991; Recchia and Hall, 1995). There is 
an imperfect inverted repeat with a core region of RYYYAAC near the 3, end of the gene 
and a core region of GTTRRRY at the other end (Hall et al, 1991; Collis and Hall, 1992). 
A gene cassette does not contain a promoter and is therefore transcribed from a promoter 
in the integron. 
Only the closed circular form of gene cassette can be integrated into an integron 
(Collis and Hall, 1992). The integrase interacts with the target recombination sites that 
are the attl site located in the 5'-CS of the integron and the attC site located at the 3'-end 
of each gene cassette (Segal et al, 1999). 
Nearly all integron-borne gene cassettes encode resistance to groups of antibiotics 
that have been in clinical use for a long time such as the sulphonamides. Recently, a 
number of gene cassettes that encode resistance to the cephalosporins and carbapenems 
have been reported (Arakawa et al, 1995; Naas et al, 1999). 
Class 1 integrons are the most common integrons that have been reported in many 
clinically important Gram-negative bacteria such as A. baumannii (Petersen et al, 2000), 
E. coli (Barlow et al., 2004), K. pneumoniae (Lincopan et al., 2005), P. aeruginosa 
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(Toleman et al” 2007), Samomlla sp (Tamang et al., 2007) and Shigella sp (Ahmed et al., 
2006). 
3.1.2 Other classes of integrons 
Class 2 integrons are often found within the Tn7 transposons. The structure of 
class 2 integrons is similar to that of class 1 integrons. They also consist of an integrase 
gene {intll) and a recombination site {attI2) that is located between the intI2 gene and the 
first inserted resistance gene as described for class 1 integrons (Sundstrom and Skold, 
1990; Radstrom et al, 1994; Recchia and Hall, 1995; Gravel et al, 1998). The homology 
of the amino acid sequence of Intll and IntI2 are of <50% identity. Although gene 
cassettes found in class 2 integrons are identical to those in class 1 integrons, the 
functional IntI2 cannot excise the resistance gene from class 1 integrons and integrate it 
into a class 2 integron (Hansson et al, 2002). Class 2 integrons have been found in 
Acintohacter sp (Gonzalez et al, 1998), Shigella sp (Mclver et al, 2002) and Salmonella 
sp (Orman et al, 2002). 
The structure of class 3 integrons is comparable to that of both class 1 and class 2 
integrons. The amino acid sequences of Intl3 have an identity of 61% to the Intll . 
However, class 3 integrons are rarely reported and have only been described in P. 
aeruginosa, S. marcescens, Alcaligenes xylosoxidans, P. putida and K. pneumoniae 
isolates from Japan (Arakawa et al, 1995; Senda et al, 1996b). 
The class 4 integron, which is also known as Vibrio cholerae super-integron, may 
harbor as many as 100 gene cassettes, in contrast to resistance integrons in which less 
than 10 cassettes are present. Many species harbor species-specific super-integrons but 
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resistance integrons are not species-specific. Super-integrons have been mainly described 
in Vibrio sp and Shewanella sp (Clark et al, 2000; Drouin, Heidelberg et al, 2000). 
3.2 Integrons in imipenem-resistant P. aeruginosa 
Class 1 integrons have been described in most of the imipenem-resistant P. 
aeruginosa isolates reported. Genes such as bla/MP-i from Japan (Fukigai et al, 2007), 
hlaiMP-7 from Canada (Gibb et al, 2002) and Malaysia (Ho et al, 2002), hla/MP-n from 
Italy (Toleman et al, 2003), blavm-i from France (Poirel et al, 2000), and hlaviM-4 from 
Greece (Pournaras et al, 2002) are all present on a class 1 integron. Most of the class 1 
integrons are located on transferable plasmids but some are also found on transposons 
(Arakawa et al, 1995; Laraki et al., 1999). Class 2 integrons have not been found in P. 
aeruginosa so far while class 3 integrons harbouring blajMP-i have been reported from 
Japan (Senda et al” 1996b; Shibata et al, 2003). 
4 Objectives 
R aeruginosa is an important cause of nosocomial infections. Due to its intrinsic 
resistance to many antimicrobial agents, the choice of drugs for treatment of infections 
caused is very limited. Imipenem has been the most active antibiotic to treat P. 
aeruginosa infections, however strains resistant to it have developed in many places 
including Hong Kong. This is of serious concern and in order to prevent the spread of 
imipenem-resistant P. aeruginosa, it is important to understand the mechanisms of 
imipenem-resistance in this organism. The objectives of my project were to: 
1. Study the antimicrobial susceptibilities of imipenem-resistant P. aeruginosa; and 
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2. Investigate the mechanisms of imipenem-resistance in these strains including P-
lactamase production; outer membrane profiles and mRNA expression of the oprD gene; 
and the effect of the mexT gene on the regulation of OprD protein production. 
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Chapter 2-Materials and methods 
1 Materials 
All materials used in this study are listed in Table 2.1. 
1.1 Bacterial strains 
1.1.1 Bacterial strains used in this study 
Pseudomonas aeruginosa strains were cultured from clinical specimens of 
patients in the New Territories East Cluster Hospitals (Prince of Wales Hospital (PWH), 
Shatin Hospital, Tai Po Hospital, Alice Ho Miu Ling Nethersole Hospital, Bradbury 
Hospice, Cheshire Home and North District Hospital), during the period of January 2001 
and May 2005. These specimens include wound swabs, blood cultures, urine, sputa, body 
fluid and pus. 
All 140 single patient isolates reported by the clinical diagnostic laboratory of 
PWH to be resistant to imipenem and survived were used for this study. They were stored 
on nutrient agar slants and kept at room temperature and in glycerol broth at -70°C for 
further studies. 
1.1.2 Reference strains 
E. coli ATCC 25922, NCTCC (National Collection of Type Culture) 10418, S. 
aureus ATCC 29213, and P. aeruginosa ATCC 27853 were used as control strains in 
antibiotic susceptibility testing. 
3-Lactamases extracted from clinical isolates confirmed to produce SHV-5, P99, 
TEM-l , TEM-2 and K1 enzymes were used as pi markers in isoelectric focusing 
experiments. 
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Clinical isolates confirmed to produce P-lactamases IMP-1, TEM-l , CTX-1, 
SHV-4, OXA-1, OXA-2 and OXA-10 were used as positive controls for detection of the 
respective p-lactamase genes. P. aeruginosa COL-1 (kindly supplied by Dr. Laurent 
Poirel, University of Paris-Sud, France) and P. aeruginosa 03/9/T104 (kindly supplied by 
Dr. Kyungwon Lee, Yonsei University College of Medicine, Korea) were used as 
positive controls for blaym and bla^m gene detection, respectively. 
Clinical isolate 4639 confirmed to harbor the aadA2 gene encoded by class 1 
integron gene cassette was used as a positive control for detecting intll and class 1 
integron gene cassette. E. coli 96K062 and E. coli 96K381 (kindly supplied by Dr. JC 
Lee, Kyungpook National University, Korea) were used as positive controls for intI2. 
2 Methods 
2.1 Subculture of isolates 
Strains that were stored on nutrient agar at room temperature or in glycerol broth 
at _70�C were subcultured on Mueller-Hinton (MH) agar and incubated at 35°C overnight. 
2.2 Identification 
All strains were initially identified by the API 20E system and their susceptibility 
to antibiotics was determined by a disk diffusion method (CLSI, 2005) in the clinical 
microbiology laboratory of PWH. After subculture, their identity was reconfirmed by the 
oxidase test (Koneman et al” 1997). 
2.3 Antibiotic susceptibility testing 
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The susceptibilities of the strains to 19 antibiotics (Table 2.2) were tested by 
determining the minimum inhibitory concentration (MIC) using an agar dilution method 
(CLSI, 2005). 
2.3.1 Preparation of antibiotic plates 
Antibiotic powder was weighed (calculated according to the following formula) 
and dissolved in an appropriate solvent (Table 2.2) to make up a stock solution of 50,000 
mg/1 or 5,000 mg/1 and kept in a -70°C freezer. 
Weight (mg) = Volume (ml) x Concentration fm^/L) 
Potency (units/mg) 
The antibiotic stock solution was diluted in a series of 1:10 dilution with distilled 
water. MH agar was prepared according to the manufacturer's instruction. An appropriate 
volume of an antibiotic was added to MH agar in order to prepare plates with the desired 
final concentration. Agar plates containing serial two-fold dilutions of antibiotics in the 
concentration range as listed in Table 2.2 were prepared. All antibiotic plates were kept in 
a 40c cold room and used within two days after preparation. 
2.3.2 Inoculation of antibiotic plates 
Several overnight single colonies on MH agar were emulsified in 1.5 ml of 0.85% 
sterile saline to a turbidity equivalent to that of a 0.5 McFarland standard (approximately 
1.5x108 cfu/ml). The bacterial suspensions were further diluted 10-fold with 0.85% 
sterile saline and were then inoculated onto antibiotic-containing agar by the MIC2000 
inoculator which deposited approximately 1 \x\ onto the agar surface. The final inoculum 
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on the agar would then be approximately cfu per spot. The plates were incubated at 
35°C for 16 to 20 hours. 
2.3.3 Determination of minimum inhibitory concentration (MIC) 
The MIC of an antibiotic for a strain is the lowest concentration of antibiotic that 
inhibits its growth. A strain was regarded as resistant to an antibiotic if its MIC was 
greater than the breakpoint concentration for susceptible strains according to the CLSI 
(CLSI, 2005). The MIC50 and MIC90 are the concentrations of an antibiotic that inhibit 
growth of 50% and 90% of the tested strains, respectively. 
2.4 Phenotypic detection of metallo-P-lactamase (MBL) production 
p. aeruginosa strains that had an imipenem MICs >8 mg/L were screened for 
metallo-(3-lactamase (MBL) production by the imipenem-EDTA disk method (Yong et 
al, 2002). A P. aeruginosa strain confirmed to produce IMP (a MBL) and one that does 
not produce MBLs, ATCC 27853, were used as controls. 
2.4.1 Preparation of inoculum 
Several overnight colonies on MH agar plate were emulsified in 1 ml of sterile 
saline to a turbidity equivalent to that of a 0.5 MacFarland standard. 
2.4.2 Imipenem-EDTA disk test 
The bacterial suspension was spread evenly onto the surface of an MH agar using 
a sterile cotton swab. Two 10-|Lig imipenem disks were placed on the surface of the 
bacterial lawn about 40 mm apart from each other. Four microliters of a 0.5 M EDTA 
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solution (prepared by dissolving 186.1 g of disodium EDTA.2H2O in 1,000 ml of 
distilled water and adjusting it to pH 8.0 by NaOH (Sambrook et al., 2001), equivalent to 
750 |ig) were added to one of the disks. The plates were incubated at 35°C for 16 to 20 
hours. 
2.4.3 Determination of MBL strains 
After incubation, the diameters of the zone of inhibition were measured. MBLs 
require zinc for their catalytic activity and are inhibited by EDTA (Bush, Jacoby and 
Medeiros, 1995; Buynak et al., 2004). A difference in zone diameter of >8 mm indicated 
production of MBL by the tested strain (Yong et al, 2002). 
2.5 Extraction of crude p-lactamase 
Crude P-lactamase was extracted from imipenem-resistant strains by 
ultrasonication. 
P. aeruginosa strains were grown on MH agar at 35°C overnight. A loopful of this 
bacterial culture was emulsified in 600 \i\ of 0.1 M sodium phosphate buffer (pH 7.0), 
centrifuged at 5,000 x g for 5 minutes, the supernatant removed, the cell pellet 
resuspended in 400 of distilled water and centrifuged again at 5,000 x g for 5 minutes. 
The cell pellet was finally resuspended in 30 |al of distilled water and then sonicated in a 
sonicator (MSE Soniprep 150) at an amplitude of 10 microns for 15 seconds for 4-6 times 
with the sample tube chilled in ice. 
2.5.1 Detection of p-lactamase production 
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One microliter of 500 mg/L of nitrocefin was added to the crude extract (prepared 
as described in 2.5 above) on a porcelain plate and mixed with a wire loop. Presence of P-
lactamase was indicated by nitrocefin changing from yellow to red within 1-2 minutes. 
All crude extracts giving a positive nitrocefin reaction were stored at -70°C for future use. 
2.6 Isoelectric focusing (lEF) 
The isoelectric points (pis) of imipenem-resistant isolates were estimated by lEF 
on a precast polyacrylamide gel of pH 3 to 10. 
2.6.1 Set up of electrophoresis equipment 
The precast polyacrylamide gel was removed from its package and placed on the 
Multiphor II electrophoresis unit. The cathode and anode electrode strips were prepared 
by soaking in 1 mol/L of sodium potassium and 1 mol/L of phosphoric acid, respectively. 
They were then applied to the edges of the gel. Pieces of sample application paper were 
placed at 40 mm from the cathode (instead of 10 mm as suggested by the manufacturer) 
to give better separation of protein bands and at a distance of about 5 mm from each other. 
2.6.2 Sample application and instrument preparation 
Twenty microliter of a crude enzyme extract was applied to each piece of sample 
application paper. The electrode holder was placed on the Multiphor II unit and the 
electrodes were aligned in the center of the electrode strips. The two electrodes were 
connected to the base unit and the safety lid was placed in position. 
2.6.3 Running conditions 
30 
The Multiphor II electrophoresis unit was connected to the MultiTemp II 
thermostatic circulator to give a running temperature of 10°C during electophoresis. The 
gel was run at 1,500 V, 50 mA and 30 W for about 1.5 hours. 
2.6.4 Detection of p-lactamase 
After electrophoresis, the gel was overlaid with a piece of filter paper that was 
soaked with 4 ml of 500 mg/L of nitrocefin. Presence of (3-lactamase was indicated by 
appearance of red bands within 1-2 minutes. 
2.6.5 Determination of isoelectric point (pi) 
Crude extracts prepared from strains harbouring p-lactamase genes b!asm-5 (pi 
8.2), blap99 (pi 7.8), blaKi (pi 6.5), blajEu-i (pl 5.6) and hlajEu-\ (pi 5.4), were used as pi 
markers. These markers were included on every gel with tested samples. The distance of 
the p-lactamase bands from the cathodic edge of the gel was measured. A graph of 
distance (Y-axis) versus pi of pi markers (X-axis) was plotted. The pi of the p-lactamase 
of the tested sample could be read off from the graph. 
2.7 Bioassay of imipenem hydrolysis 
This was used to test the ability of p-lactamases of our imipenem-resistant isolates 
to hydrolyse imipenem. 
2.7.1 Preparat ion of inoculum and plate 
An imipenem susceptible standard strain {E. coli ATCC 35218) was used to 
inoculate an MH agar plate. Several overnight single colonies on MH agar were 
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emulsified in 1.5 ml of 0.85% sterile saline to a turbidity equivalent to that of a 0.5 
McFarland standard. The bacterial suspension was spread evenly onto the surface of an 
MH agar by a sterile cotton swab. Five holes, 20 mm apart from each other, were made 
on each agar plate with a sterile hole puncher. 
2.7.2 Preparation and incubation of sample mixtures 
Crude P-lactamase extract (20 |il) was mixed with 20 lul of 1,000 mg/L (0.5 mg/L) 
of imipenem in a 0.5 ml eppendorf tube. Crude extracts prepared from strains producing 
IMP-1 and OXA-2 were used as positive and negative controls, respectively. The mixture 
was then incubated at 37°C for 2 hrs. Mixtures containing 20 \x\ of distilled water instead 
of p-lactamase extract and imipenem and 20 jul of distilled water and the same amount of 
imipenem but was denatured by boiling at 100�C for 30 minutes were also incubated 
under the same condition. 
2.7.3 Application of sample mixtures 
After incubation, the mixtures were vortexed and centrifuged briefly. Twenty 
microliters of each of the mixtures prepared as described in 2.7.2 above were added to 
each hole in the agar. The plate was then incubated (with the lid facing upwards) at 35°C 
overnight. 
2.7.4 Determination of imipenem hydrolysis 
The diameter of the following zones of inhibition was measured after incubation: 
1. That around the hole containing the crude extract of the tested strain 
and 0.5 mg/L of imipenem; 
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2. That around the hole containing the crude extract of a imipenem 
hydrolyzing strain, IMP-1, and 0.5 mg/L of imipenem (positive control); 
3. That around the hole containing the crude extract of a imipenem non-
hydrolyzing and 0.5 mg/L of imipenem (negative control); 
4. That around the hole containing distilled water and 0.5 mg/L of 
imipenem; and 
5. That around the hole containing distilled water and 0.5 mg/L of 
denatured imipenem. 
Imipenem in the mixture was regarded as active if the diameter of the zone of 
inhibition around the hole was >15 mm, the zone diameter interpretive standard 
for susceptible strains (CLSI, 2005). 
2.8 Detection of p-lactamase genes 
2.8.1 Polymerase chain reaction (PCR) 
Presence of (3-lactamase genes hla\uv, hla^iu, hla^m, blajEM, blacxx, blasm, and 
blaoxA in imipenem-resistant isolates were screened by PCR. 
2.8.2 Preparation of DNA template 
DNA template was prepared by emulsifying one to two overnight colonies on a 
MH agar plate in 200 |li1 of double distilled water and heating at 100�C in a boiling water 
bath for 10 minutes. The DNA template was stored at -20°C until further use. 
2.8.3 Preparation of PCR master mix 
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The PCR master mix in a total volume of 25 \i\ was prepared as listed in Table 2.3. 
The DNA template of the reference strains that were positive for the genes amplified 
were used as positive controls. Nuclease-free water as template instead of sample DNA 
was used as a negative control. Positive and negative controls were included in each set 
of PCR. 
The primers used in detecting P-lactamase genes are listed in Table 2.4. 
2.8.4 PCR running conditions 
Amplification was performed in a thermal cycler (Gene Amp PCR system 9600) 
using the following conditions: 7 minutes of denaturation at 95°C followed by 35 cycles 
of 1 minute at 95°C, 1 minute of annealing at 52°C and 1 minute of extension with a final 
extension of 7 minutes at 72°C. 
2.8.5 Agarose gel electrophoresis 
PCR products were separated by gel electrophoresis in a GNA 100 electrophoresis 
apparatus (Amersham Pharmacia Biotech). A 1% agarose gel was prepared by adding 
500 mg of agarose powder to 100 ml of 0.5 X TBE buffer (0.045 M Tris-borate, 0.00 IM 
EDTA) and then heating in a microwave oven until the gel was completely melted. The 
gel was poured into a gel tray with a comb placed 15 mm from one end of the gel tray. 
The setup was put in place until the gel was completely set. The gel was then placed into 
the gel tank containing 0.5 X TBE buffer. PCR product (5 was mixed with 1 |li1 of 6x 
loading buffer (0.25% bromophenol blue and 15% ficoll type 400) and then loaded into 
the well of the gel. Ol74/HaelU digest was used as molecular weight marker. The gel 
was electrophoresed for 1 hr at 110 V. 
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After electrophoresis, the gel was stained with 0.5 mg/L of ethidium bromide for 
about 30 minutes, rinsed with distilled water and visualized and photographed under UV 
transillumination using a gel documentation system (Thermal Imaging system CTI-500). 
2.8.6 DNA sequencing 
PCR products were purified before sending off to Macrogen for DNA sequence 
determination. 
PCR products were purified using the MicroSpin S-300 HR columns. To prepare 
the column for use, the resin in it was resuspended by vortexing, the bottom closure was 
snapped off and the column was then spun for 1 minute at 735 x g. PCR product (about 
25 \i\) was applied to the column, centrifuged at 735 x g for 2 minutes and the purified 
product was collected in a 1.5 ml eppendorf tube. DNA concentration in the purified 
product was checked by gel electrophoresis as described in section 2.8.5. 
The purified PCR products were sent to Macrogen Inc. for DNA sequence 
determination by the single extension method (Sambrook et al., 1989). Results from 
Marcogen were then analyzed by the Chromas 1.42 software. 
The Basic Local Alignment Search Tool, BLAST 
(http://www.ncbi.nlm.nih.gov/BLAST/), was used to find regions of similarity between 
sequences. The program compares nucleotide sequences to sequence databases and 
calculates the statistical significance of matches. 
2.9 Detection and characterization of integrons 
2.9.1 PCR 
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Presence of intll and intI2 in the imipenem-resistant isolates was screened by 
Components of the PCR mix are shown in Table 2.5 and primers Intll and IntI2 used are 
shown in Table 2.6. DNA extracted from strains harboring intll and int I2 was used as 
positive controls and nuclease-free water in place of DNA template was used as the 
negative control. 
PCR running conditions consisted of 7 minutes of denaturation at 95°C followed 
by 35 cycles of 1 minute at 95°C, 1 minute of annealing at 56°C for intll and 60°C for 
intI2, 1 minute of extension with a final extension of 7 minutes at 72°C. PCR products 
were separated by agarose gel electrophoresis as described in section 2.8.5. 
2.9.2 DNA sequencing 
PCR products were purified and their DNA sequences determined as described in 
section 2.8.6. 
2.10 Detection and characterization of gene cassettes 
2.10.1 PCR 
Presence of gene cassettes and the 3'-conserved segments in the imipenem-
resistant isolates that harbor class 1 integron was screened by PCR using two sets of 
primers as shown in Table 2.7. Components of the PCR mix are shown in Table 2.8 and 
Table 2.9. DNA extracted from strains harboring class 1 integron gene cassette was used 
as positive controls and nuclease-free water in place of DNA template was used as the 
negative control. 
36 
PGR running conditions for amplifying gene cassettes consisted of 5 minutes of 
denaturation at 94°C followed by 35 cycles of 30 seconds at 94°C, 30 seconds of 
annealing at 57°C, 3 minutes of extension with a final extension of 7 minutes at 72°C. 
PCR running conditions for amplifying 3'-conserved segments consisted of 5 
minutes of denaturation at 94°C followed by 35 cycles of 1 minute at 94°C, 1 minute of 
annealing at 55°C, 1 minute of extension with a final extension of 7 minutes at 72°C. 
PCR products were separated by agarose gel electrophoresis as described in 
section 2.8.5. 
2.10.2 DNA sequencing 
PCR products were purified and their DNA sequences determined as described in 
section 2.8.6. 
2.11 Investigation of membrane permeability 
2.11.1 Extraction of outer membrane proteins (OMP) 
Several overnight colonies on a MH agar was selected and emulsified in 600 |LI1 of 
10 mM Tris-HCl (pH 8.0) and centrifuged for 10 minutes at 5,000 x g. The cells were 
washed with 10 mM Tris-HCl (pH 8.0) and resuspended in 400 fil of the same buffer. 
Crude OMP extracts were prepared by sonication using Soniprep 150 at an amplitude of 
10 microns for 15 seconds for 4-6 times with the samples tubes placed in ice. 
The extracts were then centrifuged at 3,800 x g for 10 minutes. The supernatant 
was aspirated and the total volume made up to 1 ml with 10 mM Tris-HCl (pH 8.0). 
Triton-100 (100%, 10 |il) was added, the mixture incubated for 30 minutes at 37°C and 
then centrifuged at 38,000 x g for 30 minutes at 4 � C in a Centrikon T-2080 centrifuge. 
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The pellet containing OMPs was resuspended in 400 |li1 of 10 mM Tris-HCl (pH 8.0) and 
stored at -20°C until use. 
2.11.2 Quantification of OMP 
The crude OMP extracts were quantified by the mi crop late procedure of Bio-Rad 
BCA™ Protein Assay. 
2.11.3 Preparation of the albumin standards and working reagents 
Different concentrations of albumin standards (0 mg/L, 25 mg/L, 125 mg/L, 250 
mg/L, 500 mg/L, 750 mg/L, 1,000 mg/L, 1,500 mg/L and 2,000 mg/L) were prepared by 
diluting the stock albumin standard (2 mg/L in 0.9% saline and 0.05% sodium azide) with 
appropriate volumes of distilled water. 
A duplicate sample was prepared for each standard and unknown. The albumin 
standard (20 |al) and the tested samples (20 [i\) were added to each well of a microplate 
that contained 180 of working reagents. Working reagents were prepared by mixing 50 
parts of BCA™ reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and 1 part of BCA™ 
reagent B (containing 4% cupric sulfate). The mixture in the wells of the plate was mixed 
thoroughly by placing the plate on a plate shaker (Thermo Electron Corporation) to be 
shaken gently for 30 seconds. The plate was then covered with a plastic lid and incubated 
at 3 7 � C for 30 minutes. 
After incubation, the absorbance of each well was measured at 560 nm using a 
plate reader (Multiskan ascent) after the plate was shaken for 30 seconds to mix the 
mixtures in wells. 
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2.11.4 Determination of protein concentration 
A curve of the concentration of albumin standards as the Y-axis and the 
absorbance as the X-axis was drawn. The concentration of the unknown samples was 
read from the curve. 
2.12 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
The extracted OMPs were separated and their size determined by SDS-PAGE. 
2.12.1 Sample preparation 
The extracted OMPs (17.5 |al) were mixed with 1 X (1.25 ^il) of XT-reducing 
agent and 1 X of XT-sample buffer (6.25 |il) to make up to a total volume of 25 |li1. The 
mixtures were denatured at 100°C for 10 minutes in a thermal controller (Gene Amp PCR 
system 9600). 
2.12.2 Gel preparation and sample application 
A criterionTM XT precast gel was placed in the criterion 丁ce l l medium gel tank. 
The 20X XT MOPS running buffer was first diluted 1:20 with distilled water and was 
used to fill up the tank. Samples (25 ^il) were then applied to each well of the gel. The 
SDS-PAGE molecular weight standard (Prestained SDS-PAGE standards broad range) 
was used as a control. The gel was electrophoresed using a PowerPac HC™ for 1.5 hrs at 
150 V and 0.3 A. 
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2.12.3 Staining and destaining of the gel 
After electrophoresis, the gel was removed from the gel tank and then rinsed with 
200 ml of distilled water before staining with 50 ml of coomassie blue G-250 with 
shaking for 2 hrs. After staining, the coomassie blue was rinsed off with 200 ml of 
distilled water and then soaked in 50 ml of destaining solution (10% acetic acid, 30% 
methanol and 60% distilled water) for 2 hrs. After destaining, an image of the gel was 
photographed using Chemidoc XRS and analyzed using Quantity One software. 
2.13 Expression of the oprD gene 
The expression level of the outer membrane encoding gene oprD was quantified 
by real time RT-PCR. 
2.13.1 Extraction ofRNA 
Total RNA from the strains was extracted using the RNeasy Mini kit with slight 
modifications. 
An overnight single colony on a MH agar plate was inoculated in 2 ml of Luria-
Bertani (LB) broth and incubated at 37°C for 4 hrs with shaking after which 1 ml was 
pipetted into a 1.5 ml eppendorf tube. Bacterial cells were harvested by centrifuging at 
5,000 X g for 5 minutes at 4°C using an Eppendorf centrifuge. The supernatant was 
decanted followed by aspiration. The cell pellet was loosened by flicking the bottom of 
the tube and was resuspended thoroughly in 100 of lysozyme-containing TE buffer (1 
mg/L of lysozyme in 10 mM Tris-HCl, 1 mM EDTA; pH 8.0) by vortexing. This was 
incubated at room temperature for 15 minutes. 
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p-mercaptoethanol (p-ME) (10 |il/ml of Buffer RLT) (350 |il) was added to the 
sample and thoroughly mixed by vortexing. Ethanol (95%) (250 |LI1) was added to the 
lysate and thoroughly mixed by pipetting up and down. About 700 |li1 of the sample was 
applied to the RNeasy mini column which was placed in a 2-ml collection tube. The 
column was centrifuged for 15 seconds at 8,000 x g. 
After centrifugation, the flow-through was discarded and 700 )il of Buffer RWl 
was added to the RNeasy column and centrifuged for 15 seconds at 8,000 x g to wash the 
column. The flow-through was discarded and 500 \i\ of Buffer RPE was added to the 
RNeasy column. It was centrifuged for 2 minutes at 8,000 x g to dry the RNeasy silica-
gel membrane. 
The RNeasy column was transferred to a new 1.5-ml collection tube and 40 [l\ of 
RNase-free water was directly pipetted onto the RNeasy silica-gel membrane. RNA was 
eluted from the tube by centrifuging for 1 minute at 8,000 x g. 
2.13.1.1 Inhibition of RNase degradation 
To prevent degradation of the extracted RNA by RNase, 1 |il (1 U) of 
Recombinant RNasin® Ribonuclease inhibitor was added to 40 |li1 of RNA sample. 
2.13.1.2 Removal of DNA 
To remove any DNA that might be present in the RNA sample, 1 U of DNase I 
was added to 2 |il of an RNA sample and RNase-free water was added to make up to a 
total volume of 10 The mixture was incubated at room temperature for 15 minutes. 
The DNase activity was inactivated by adding 1 |al of 25 mM EDTA (RNase-free) and 
incubating for 15 minutes at 65°C. Presence of DNA in the RNA sample was checked by 
41 
PCR using primers specific for the housekeeping gene rpoD (as described in section 
2.8.5). 
2.13.1.3 Quantification of RNA samples 
The amount of RNA was measured by using NanoDrop ND-1000 according to the 
manufacturer's instructions. Two microliters of RNase-free water were applied onto the 
measurement pedestal and was measured. This measurement was taken as a blank. When 
the measurement was done, the blank sample was wiped off and RNA samples (2 |li1 each) 
were similarly measured. Results were analyzed by the ND-1000 3.3.0 software. The 
absorbance was measured at both 260 nm and 280 nm and the ratio of absorbance at 260 
nm and 280 nm was used to assess the purity of RNA. A ratio of about 2.0 was accepted 
as pure for RNA. 
2.13.2 Real-time RT-PCR 
Real-time RT-PCR was performed using the ABI PRISM 7700 Sequence 
Detection System. The method of relative quantitation of gene expression was used to 
quantify differences in the expression level of a target gene between different samples 
with reference to the endogenous control. 
In this study, the target gene was oprD and the endogenous control was rpoD, the 
housekeeping gene that is consistently expressed in P. aeruginosa (Savli et al., 2003). 
The reporter dye of the probes was F A M ™ and no quencher dye was used. The primers 
and probes used are shown in Table 2.10. 
2.13.2.1 Preparation of real-time RT-PCR mixtures 
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TaqMan EZ RT-PCR Core Reagents kit was used to prepare the real-time PCR 
mixture in a total volume of 25 \i\ (Table 2.11). 
2.13.2.2 Real-time RT-PCR running conditions 
The thermal cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes, 
followed by 40 cycles at 95°C for 15 seconds and 6 0 � � f o r 1 minute. Each RNA sample 
was done in duplicate. 
2.13.2.3 Construction of relative standard curves 
RNA (1 jig) from P. aeruginosa ATCC 27853, which was used as the calibrator 
sample, was diluted 10-, 100-, 1,000- 10,000-fold with RNase-free water. RNA of known 
concentrations was run along with the tested samples for each reaction. The diluted RNA 
samples were used to construct a relative standard curve for oprD and rpoD of the 
logarithm of RNA concentrations versus Cj , where Cj is the number of cycles of a 
reaction when the fluorescence generated is at the threshold. The amount of RNA of the 
rpoD and oprD genes in the tested samples could then be extrapolated from the 
respective standard curves. 
2.13.3 Analysis of real-time RT-PCR results 
Results were analyzed using Sequence Detection System software version 1.7. The 
baseline range and threshold level were adjusted to achieve the highest correlation 
coefficient of the standard curve. The Ct values from the duplicated samples were 
averaged and the copy number (the amount of RNA) was extrapolated from the standard 
43 
curve. The test samples and R aeruginosa ATCC 27853 were normalized by rpoD to 
calculate a normalized oprD value using the following formulae: 
Normalized oprD (test sample) = oprD/rpoD 
Normalized opoD (P. aeruginosa ATCC 27853 ) = oprD/rpoD 
The normalized oprD value of the test sample was then divided by that of P. 
aeruginosa ATCC 27853 to give the fold-difference in target quantity between the test 
sample and the calibrator sample. The normalized oprD of P. aeruginosa ATCC 27853 
was assigned a value of 1. The expression of oprD of samples relative to P. aeruginosa 
ATC 27853 less than 1 was regarded as reduced expression. 
2.14 Characterization of outer membrane protein regulator mexT 
2.14.1 PCR 
The outer membrane protein regulator mexT was amplified by PCR that was 
performed in a total volume of 25 |LI1 (Table 2.12). DNA extract of P. aeruginosa ATCC 
27853 was used as the positive control and nuclease-free water instead of DNA template 
was used as the negative control. 
The primers used for PCR is listed in Table 2.13. 
PCR running conditions consisted of 7 minutes of denaturation at 95°C followed 
by 35 cycles of 1 minute at 95°C, 1 minute of annealing at 5OX and 1 minute of 
extension with a final extension of 7 minutes at 72°C. PCR products were separated by 
agarose gel electrophoresis as described in section 2.8.5. 
2.14.2 DNA sequencing 
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1 Prevalence of imipenem-resistant P. aeruginosa isolated from 
patients in hospitals of the New Territories East Cluster (NTEC) from 
2001 to 2005 
A total of 140 non-duplicate isolates were cultured from clinical specimens of 
patients in the NTEC hospitals during the period of January 2001 - May 2005, with 13 
isolated in 2001, 35 in 2002, 39 in 2003, 28 in 2004 and 25 in 2005. The majority of the 
clinical specimens were from the respiratory tract (62.1%) including sputa (32.1%) and 
bronchial and tracheal aspirates (30%) (Table 3.1). The other specimens were urines 
(19.2%), wound swabs (12.1%) and body fluids, pus and miscellaneous specimens that 
were not specifically indicated (6.4%). 
1.1 Age and sex distribution of patients 
The age and sex distribution of patients are shown in Table 3.2. More than 60% 
were aged 61 or older. The average age was 64 and the median was 68. Only 1.4% of 
patients were aged 0 - 9 years and 31.4% were aged 10 - 60 years. The male to female 
patient ratio was 1:0.43. 
1.2 Antimicrobial susceptibilities 
1.2.1 Susceptibility to carbapenems 
The imipenem MICs ranged from 8 mg/L to 128 mg/L with the MIC50 and MIC90 
being 16 mg/L and 32 mg/L, respectively. Two isolates had an imipenem MIC of 64 
mg/L and one 128 mg/L, both of which were isolated during 2002. 
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Only 1 ^ 2 % of these imipenem-resistant strains were resistant to 4 mg/L of 
meropenem, with an MIC range of 8 mg/L - >128 mg/L, MIC50 of 16 mg/L and MIC90 of 
>128 mg/L. The percentage of meropenem resistance ranged from 74.3% to 76.9% 
during 2001 - 2004 but was 88% in 2005. However, this was not significantly different. 
1.2.2 Susceptibility to other p-lactams 
The percentage of resistance to cefotaxime, ceftriaxone, ceftazidime and 
aztreonam was 96.7%, 97.4%, 45.7% and 63%, respectively (Table 3.3). One hundred 
thirty-nine out of the 140 strains tested ( -100%) were resistant to cefoxitin. The 
proportion of strains resistant to piperacillin was 15.4% - 28.6% during 2001 - 2004 but it 
increased to 40% in 2005 while the corresponding figures for piperacillin in the presence 
of tazobactam were 15.4% - 25% and 36%. Resistance to ticarcillin during the period 
2001 - 2005 was 55.6% and that to ticarcillin in the presence of clavulanic acid was 
47.30/0. Resistance to cefepime was 69.2% - 60.7% during 2001 - 2004 but was 80% in 
2005. The percentage resistance to ceftazidime was 61.5% in 2001 but decreased to 
31.4% in 2002. It then increased to 48.7% - 44% during 2003 - 2005. 
1.2.3 Susceptibility to aminoglycosides and fluoroquinolones 
Only 6.7% of the strains tested were resistant to tobramycin while 11.8% - 22.7% 
were resistant to the other three aminoglycosides tested (amikacin, gentamicin and 
netilmicin). There was a decreasing trend of resistance to all four aminoglycosides tested 
during the period 2001-2005 with resistance to tobramycin dropping to 0% and that to the 
other three aminoglycosides to 8% - 12% in 2005 (all p values >0.05). 
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Resistance to the fluoroquinolones tested (levofloxacin, norfloxacin and ofloxacin 
are ranged from 13.3% to 28%. The percentage of levofloxacin resistance increased from 
7.70/0 in 2001 to 20% 2005. The percentage of norfloxacin resistance was highest (21.4%) 
in 2004 and percentage of resistance to ofloxacin was lowest (14.3%) at 2002 during the 
period 2001 - 2005. 
1.2.4 Resistance patterns 
The resistance patterns of the 140 isolates tested are listed in Table 3.4. There 
were a total of 71 different resistance patterns, ranging from resistance to two to 19 
antibiotics. Most of the isolates (14.3%) were resistant to four antibiotics, followed by 
those resistant to 10 (12.9%) and 12 (12.1%) antibiotics. More than 50% (53.1%) were 
resistant to ten or more antibiotics. Only one isolate was resistant to 19 antibiotics. The 
most common resistance pattern was resistance to imipenem (IMP), cefotaxime (CTX), 
cefoxitin (CX) and ceftriaxone (CRO) (14.3%) followed by resistance to imipenem, 
meropenem (MEM), cefotaxime and ceftriaxone (7.1%). 
2 Phenotypic detection of metallo-P-lactamase (MBL) producing 
strains 
This was performed by the imipenem-EDTA disk method as described in section 
2.4. 
The zone of inhibition around the imipenem disk for the strain harboring the 
hlaxu?.\ gene that was used as a MBL positive control was 6 mm which was 12 mm 
smaller than that around the disk with 10 |LLg of imipenem and 750 jug of EDTA, while the 
corresponding figures for the MBL-negative strain ATCC 27853 P. aeruginosa was 21 
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mm and 1 mm (Figure 3.1). All isolates tested gave an increase in the diameter of the 
inhibition zone around the disk containing imipenem and EDTA as compared to that 
around the imipenem disk of 2 mm - 12 mm (Table 3.5). Using the criterion of >8 mm 
difference to indicate production of MBL by a strain (Yong et al., 2002), 20 strains were 
MBL positive. Two of these had an imipenem MIC of 64 mg/L and one, 128 mg/L. For 
the MBL-negative strains, 102 (85%) had imipenem MICs of 8 mg/L - 16 mg/L. 
2.1 Characterization of p-lactamases 
2.1.1 Production of p-lactamases 
One hundred twenty-five (89.3%) of the 140 isolates tested were screened 
positive for p-lactamases. 
2.1.2 Determination of isoelectric points of P-lactamases 
???i???soelectric focusing was preformed on crude p-lactamase extracts from the 
125 p-lactamase producing strains. Ninety-one of these isolates each produced one to 
four p-lactamases of pis ranging from 7.6 to 8.2 and of 21 different combinations (Table 
3.6). The majority of the isolates (75.8%) produced only one p-lactamase and 6.6% -
7.70/0 produced two to four p-lactamases. Of the isolates that produced two p-lactamases, 
one each produced p-lactamases of four different combinations and two of another 
combination while of those that produced three p-lactamases, one and two each produced 
p-lactamases of three different combinations. The seven isolates that each produced four 
p-lactamases were of three different combinations. A p-lactamase of pi 7.8 was the most 
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common p-lactamase (24.3%). p-Lactamases of pis 7.9, 8.0 and 8.2 were each produced 
by 23.1%, 28.6% and 24.2% of isolates, respectively. 
2.2 Imipenem hydrolysis by P-lactamases 
This was performed by a conventional bioassay (Figure 3.2). The activity of 
imipenem was first tested by comparing the diameter of the zone of inhibition around the 
well containing imipenem on a lawn of E. coli ATCC 35218 with that around the well 
containing the same amount of imipenem that had been heat-denatured. There was no 
zone of inhibition around the well containing the denatured imipenem nor around that 
containing a mixture of the same amount of imipenem and a crude p-lactamase extract 
from an IMP-1-producing strain (positive control) while the zone of inhibition around the 
well containing imipenem was of a diameter of 30 mm in average for all tested strains. 
The diameter of the zone of inhibition around the well containing a mixture of a crude P-
lactamase extract from a TEM-1-producing strain and 0.5 mg/L of imipenem was 28 mm 
and that around the well containing a mixture of a crude extract of P-lactamase from each 
of the imipenem resistant strains and 0.5 mg/L of imipenem was 28 mm - 30 mm. 
2.3 Detection of p-lactamase genes 
PGR with specific primers was used to detect presence of P-lactamase genes 
blaiu?, bla風 blasm, blajEu, blacjx, blasm, and blaoxA in all the imipenem-res i s tan t 
isolates. Only two strains produced PGR products of the expected size, a 760-bp product 
from one strain (isolate no. 2244) using primer pairs OXA-IOF and OXA-IOR and a 700-
bp product from another (isolate no. 4638) using primer pairs 0XA-2F and 0XA-2R 
(Figure 3.3). 
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2.3.1 DNA sequence determination 
Determination of the DNA sequence of the PCR product from isolate no. 2244 
showed that it was identical to that of the OXA-10 p-lactamase gene (gene bank 
accession no. AM 392427) (Appendix 1). 
Determination of the DNA sequence of the PCR product from isolate no. 4639 
showed that it was identical to that of the p-lactamase OXA-3 gene (gene bank accession 
no. L07945) (Appendix 2). 
3 Detection and characterization of integrons 
Presence of integrons in all imipenem-resistant isolates was screened by detecting 
genes intll and intI2 by PCR. Ninety-four (67.1%) strains harbored the intll gene while 
none harbored the intI2 gene. 
DNA sequence determination of these 94 PCR products showed that they were 
identical to that of the inti of class 1 integron (gene bank accession no. EF577407) 
(Appendix 3). 
3.1 Antibiotic susceptibility and resistance patterns of isolates 
harboring integrons 
The antibiotic susceptibilities and resistance patterns of P. aeruginosa isolates 
with a class 1 integron were compared to those of isolates without a class 1 integron 
(Tables 3.7 and 3.8). There was no significant difference between the proportion of 
integron-positive and integron-negative isolates that were resistant to all the antibiotics 
tested except amikacin (p<0.05). 
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All integron-positive isolates were resistant to two to 18 antibiotics in 53 different 
patterns (Table 3.8). Most of the isolates (17%) were resistant to four antibiotics while 
11.70/0 and 10.6% were resistant to five and 10 antibiotics, respectively. The most 
common resistance pattern was IMP CTX CX CXO (17%) and followed by IMP MEM 
CTX CX CRO (8.5%). 
4 Detection of gene cassettes 
One or two amplicons were produced after amplification of DNA from 74 out of 
the 94 integron-positive isolates using primers specific for gene cassettes of the class 1 
integron. A 200-bp amplicon was produced from 34 isolates (45.9%), a 1,000-bp from 32 
isolates (47.3%) and a 800-bp and a 900-bp from four isolates (5.4%) each (Figure 3.4). 
No resistance gene was present in all the 200-bp amplicons. The aadA J (Gene 
bank accession no AF313472) (Appendix 4), aadA2 (Gene bank accession no DQ091 178) 
(Appendix 5), aadA6 (Gene bank accession no DQ091179) (Appendix 6), blaoxA-s and 
blaoxA-10 genes were identified in 40 out of 74 isolates. The distribution of resistance 
genes in gene cassettes is shown in Table 3.9. The aadAl was present in three amplicons, 
aadA2 was present in 28 amplicons, aadA6 was present in seven amplicions The blaoxA-s 
and blaoxA-10 gene each were present in a 1,000-bp amplicon. The aadA2 was the most 
common resistance gene identified in the isolates (70%). There were six different 
structures of integron among the integron-positive isolates (Figure 3.5). 
5 Outer membrane permeability 
5.1 Outer membrane protein profiles 
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The sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 
the outer membrane proteins was performed on 28 strains that were selected according to 
their imipenem susceptibility. These were four with imipenem MICs of 64 mg/L and 128 
mg/L, 16 with imipenem MICs of 16 mg/L and 32 mg/L and eight with an imipenem 
MIC of 8 mg/L. A protein of � 4 6 kDa, a size that was similar to that of the OprD outer 
membrane protein, was present in the P. aeruginosa ATCC 27853 standard strain and in 
19 (68%) of the 28 strains tested (Figure 3.6). 
5.2 mRNA expression of the oprD gene 
All 28 isolates were subjected to real-time RT-PCR to determine the mRNA 
expression of the oprD gene and results are shown in Table 3.10. Nine isolates were 
found to have oprD expression reduced as compared to that in P. aeruginosa ATCC 
27853. Eight of them exhibited resistance to meropenem. The 46 kDa protein was present 
in two of these isolates (isolate no. 2389 and isolate no. 1287) with reduced oprD 
expression but was absent in two isolates (isolate no. 2132 and isolate no. 3767) that had 
1.1-fold and 4.9-fold oprD expression. 
The mode and median MICs of imipenem were 32 mg/L for isolates with reduced 
oprD expression while they were 16 mg/L for isolates that had reduced oprD expression. 
6 Regulatory gene studies 
The mexT gene in these 28 isolates was amplified. The mexT gene could not be 
amplified in isolate no. 2389 and the second half of the mexT gene could not be amplified 
in 19 isolates, which included four isolates with reduced oprD expression. 
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The DNA sequence of the PCR products from these isolates was compared to that 
of the mexTgene (gene bank accession no. AJ007825.1) (Appendix 7). 
Mutations in the mexT gene of the 28 isolates are listed in Table 3.10. All except 
non-amplifiable isolate no. 2389 possessed a Leu26—Val substitution in the MexT 
regulatory protein. This mutation was also present in the mexT gene of P. aeruginosa 
ATCC 27853. A G l u s i ^ L y s substitution was found in four isolates. Valuo—Phe and 
Seri35->Thr substitutions were only present in isolate no. 2860. 
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Chapter 4-Discussion 
1 Epidemiological characteristics of imipenem-resistant P. 
aeruginosa 
Prevalence of P. aeruginosa 
P. aeruginosa has been one of the most common organism causing nosocomial 
infections in many parts of the world (Lowbury et al., 1970; Koneman et al,, 1997). An 
unpublished surveillance study conducted in 2005 in a regional hospital in Hong Kong 
showed that R aeruginosa was the third most common organism isolated from 
hospitalized patients and was the second most common bacterial species isolated from 
respiratory specimens (19%). It was also one of the ten most common bacterial species 
isolated from blood cultures (3%) and urines (5%). 
Septicemia, nosocomial pneumonia, and urinary tract and wound infections are 
the most common diseases caused by P. aeruginosa (Koneman et al., 1997). Therefore, 
the organism is usually isolated from blood and specimens from the respiratory and 
urinary tract. In this study, >60% of the 140 isolates that were resistant to imipenem were 
isolated from the respiratory tract while >10% were from urines and wound swabs. 
However, none was isolated from blood cultures. This probably indicated that P. 
aeruginosa causing septicemia was usually susceptible to imipenem. However, since 
isolates from only four years were studied, continuous surveillance should be carried out 
in order to prove this hypothesis. 
Most of our patients infected by imipenem-resistant P. aeruginosa were elderly 
since >60% were aged 61 or older. Our finding was similar to the surveillance study of 
clinical isolates of imipenem-resistant P. aeruginosa conducted by workers in the United 
States during 2001-2003. There was a preponderance of patients older than 60 years 
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infected by the organism (Karlowsky et al, 2005). Extremes of age have been found to 
be a significant risk factor for nosocomial infections (Hatchette et al, 2000). This is 
attributed to the elderly being more likely to have underlying illness, immune dysfunction 
and loss of the body's normal protective functions, such as skin integrity. They are 
usually hospitalized for a long duration (Hatchette et al, 2000). These elderly patients 
might continuously receive imipenem or many different classes of antimicrobials. The 
use of several classes of antimicrobials has been reported to be associated with 
imipenem-resistant P. aeruginosa. A previous study showed that total antimicrobial use, 
rather than use of any specific agent, increased this risk (Muder et al, 1997). A clear 
relationship between imipenem use and the acquisition of imipenem-resistant P. 
aeruginosa has also been proposed by other workers (Cailleaux et al, 1997; Troillet et al, 
1997). It is interesting to note that there were more male than female patients (1:0.43). 
This phenomenon has also been reported previously in North America by Karlowsky et 
al, (2005) who found the ratio to be 1:0.67. This may be due to the fact that the bacteria 
can cause a variety of respiratory tract infections, which have a stronger association with 
smoking. Smoking among the elderly is much more common in males than females In 
Hong Kong since Lam et al (2007) reported that about 3635 out of 5067 (71.7%) elderly 
smokers are males. 
2. Antibiotic susceptibilities of imipenem-resistant P. aeruginosa 
The emergence of multi-drug resistant P. aeruginosa, a worldwide problem, 
complicates and limits therapeutic choice (Livermore and Woodford, 2000). Almost all 
surveillance studies reveal that there is no single drug active against all P. aeruginosa 
clinical isolates (Jones et al, 2002). The problem varies in different countries. In general, 
56 
the highest rates are observed in North America and the Asia Pacific region, while the 
lowest rates are observed in Latin America and Europe (Rossolini and Mantengoli, 2005). 
For example, in Bulgaria, 49.8% of P. aeruginosa isolates were reported as multidrug 
resistant during 2001 to 2006 (Strateva et al, 2007). However, in Malaysia and the 
United States, 5.7% and 5%, respectively of P. aeruginosa isolates are multiply resistant 
(Landman et al., 2007; Raja and Singh, 2007). 
Comparing to many parts of the word, the antibiotic susceptibility rate of P. 
aeruginosa was high in Hong Kong. An unpublished surveillance study from a regional 
hospital in Hong Kong showed that in 2005, antipseudomonal drugs such as 
piperacillin/tazobactam, ceftazidime, gentamicin, amikacin, ciprofloxacin and imipenem 
were active against >95% of the P. aeruginosa strains isolated. These figures were higher 
than those reported from an international antimicrobial surveillance program (74-95%), 
which included P. aeruginosa isolates from the United States, Canada, South America 
and Europe (Pfaller et al, 1998). However, other than amikacin and imipenem, they are 
much less active against strains isolated from patients in the intensive care unit, inhibiting 
only 62%-76% of strains. 
The prevalence of imipenem-resistant P. aeruginosa isolated in Hong Kong was 
low (3%) (infection control team of PWH, personal communication) as compared to that 
in Western countries. It ranges from 28% in Italy to 18% in Canada during 2000-2002 
(Jones et al, 2004). Studies from Korea and China also show a higher prevalence of 
imipenem-resistant R aeruginosa than in Hong Kong, the figures being 24% and 38%, 
respectively (Wang et al, 2003; Lee et al, 2006). 
All our imipenem-resistant P. aeruginosa isolates were also resistant to the other 
11 p-lactams tested with two being resistant to all these P-lactams. The most common 
resistance pattern of the strains was resistance to imipenem, cefotaxime, cefoxitin and 
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ceftriazone (14.3%). Other than this pattern, a variety of resistance patterns (71 in total) 
was seen. More than 50% were resistant to the other carbapenem, meropenem and the 
antipseudomonal cephalosporin and ceftazidime. These figures were similar to those 
reported in other places such as Italy, Brazil and Japan (Kimura et al, 2005; Kokis et al, 
2005; Toleman et al, 2005) although lower than those in Brazil where >70% of P. 
aeruginosa isolates were resistant to these p-lactams (Kokis et al, 2005). It is not 
surprising to find that most imipenem-resistant P. aeruginosa strains were also resistant 
to other p-lactams as carbapenemases class A, B and D, the p-lactamases that hydrolyse 
carbapenems, also hydrolyse cephalosporins including the extended-spectrum 
cephalosporins (Poirel and Nordmann, 2002). 
Although there were 140 strains of P. aeruginosa in this study that were regarded 
as imipenem-resistant, 79% could be inhibited by 8 mg/L or 16 mg/L of imipenem, 
indicating the degree of resistance was intermediate. Only three isolates were inhibited by 
much higher concentrations of imipenem (64 mg/L or 128 mg/L). Two isolates were 
resistant to 17 out of the 19 antibiotics tested and one was resistant to all the 19 
antibiotics. Although the number of such multiply-resistant strains was at present low, 
continuous surveillance of antibiotic resistance in P. aeruginosa should be carried out to 
monitor its development and to devise measures to halt its spread. 
It is not surprising to find an organism to be simultaneously resistant to antibiotics 
with different modes of action. Although the fact that resistance to aminoglycosides, 
fluoroquinolones and P-lactams is mechanistically independent, cross resistance to P_ 
lactams, aminoglycosides and fluoroquinolones is commonly reported (Rossolini and 
Mantengoli, 2005). In an antimicrobial surveillance program conducted by workers in 
Italy, 19 out of 21 of P. aeruginosa isolates (90%) with imipenem MICs >256 mg/L were 
also resistant to all of the eight tested antibiotics, including (3-lactams (meropenem, 
58 
ceftazidime, cefepime, aztreonam) and aminoglycosides (gentamicin, tobramycin and 
amikacin) (Toleman et al, 2005). In a hospital in Greece, six isolates of P. aeruginosa 
that were resistant to high levels of imipenem (MICs >128 mg/L) were also resistant to 
high levels of P-lactams (meropenem, ceftazidime, cefepime and piperacillin-tazobactam), 
aminoglycosides (gentamicin and amikacin) and the fluoroquinolone ciprofloxacin 
(Tsakris et al, 2000). A possible explanation for this phenomenon is the overexpression 
of efflux pump systems in these imipenem-resistant isolates. The MexAB-OprM, 
MexCD-OprJ, MexEF-OprN and MexXY-OprM pump systems can extrude a wide 
variety of antimicrobial agents, including quinolones, aminolycosides and most P-lactams 
(Kohler et al, 1997; Masuda et al, 2000a; Masuda et al, 2000b). 
Some of the aminoglycosides, especially tobramycin, and fluoroquinolones, 
especially levofloxacin, were still active against imipenem-resistant strains. As these 
drugs were active against >80% of our strains, they could be used to treat infections 
caused by imipenem-resistant P. aeruginosa. 
3 Mechanisms of imipenem resistance in P. aeruginosa 
3.1 Production of P-lactamases 
Since the most common mechanism of P-lactam resistance is the production of p-
lactamases and class B metalloenzymes (MBL) are the most common P-lactamases that 
hydrolyse carbapenems, the so-called carbapenemases (Livermore 1992; Livermore 
2000), our investigation began with a rapid method to detect production of MBL by our 
strains. This method was the imipenem-EDTA disk method reported by Yong et al. (2002) 
that is able to detect MBL-producing pseudomonads with a sensitivity and specificity of 
96o/o and 91%, respectively. The principle of the method is to use metal chelators such as 
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EDTA to remove zinc that is required by MBLs for their catalytic activity. Thus, in the 
presence of EDTA, MBL-producing strains will be susceptible to imipenem. This 
character is specific for MBL but not for class A and D p-lactamase (Livermore and 
Woodford, 2000). In this study, 20 out of the 140 strains tested showed an increase in the 
inhibition zone diameter of >8 mm around the imipenem-EDTA disk, an indication of 
presence of MBL (Yong et al., 2002). However, no PGR product could be obtained after 
amplification of DNA from all these 20 strains using primers specific for MBL genes 
blam?, blawm and bla^m, indicating absence of these genes in the strains. One reason for 
this was that a MBL other than IMP-, VIM- and SIM-type was produced by the strains. 
We used primers specific for genes coding for these MBLs since the IMP- and VIM-type 
MBLs are the most common MBLs reported (Walsh et al, 2005) while the SIM-type 
enzyme is first reported by Lee et al (2003) from A. baumannii in Korea. We did not use 
primers specific for genes coding for the SPM- and GIM-type enzymes since these are 
uncommon MBLs (Walsh et al., 2005). Whether our strains produced the SPM- and 
GIM-type enzymes or novel MBLs requires further investigation. 
MBL encoding genes are usually borne on plasmids so that MBL-producing 
organisms can spread very rapidly especially in hospitals causing outbreaks (Senda et al” 
1996a; Pagani et al., 2005). A study in a tertiary-care hospital in Korea shows that 17% 
(211 out of 1,234) of the imipenem-resistant Gram-negative isolates produce MBLs (Lee 
et al., 2003b) and in Japan, 15% (11 out of 89) of the imipenem-resistant P. aeruginosa 
isolates produce MBLs (Kimura et al, 2005). Since 14.3% of our imipenem-resistant P. 
aeruginosa isolates presumably produced MBLs, we should continue to monitor the 
imipenem susceptibility and production of MBLs of our isolates to prevent and control 
the spread of such resistant strains. 
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Of the 140 isolates that were screened for the production of p-lactamases by 
nitrocefm, only 125 were positive. Fifty-four of the p-lactamase-producing strains were 
shown by lEF to produce one p-lactamase while 22 produced two to four P-lactamases of 
pis ranging from 7.6 to 8.2. There are a number of common plasmid-mediated P-
lactamases with pis of 7.6 - 8.2. For example, SHV-2, SHV-26, OXA-19 and CTX-M-8 
enzymes have pis of 7.6, SHV-4, SHV-18 and CTX-M-44 enzymes have pis of 7.8 and 
SHV-5, SHV-9, SHV-22 and CTX-M-13 enzymes have pis of 8.2 
(http://www.lahev.org/studies). In addition, the chromosomal AmpC enzymes of P. 
aeruginosa also have pis of 7.6, 8.1 and 8.2 (Walther-Rasmussen et al, 1999). Since P-
lactamases may be heterogeneous in their pi, pi value cannot, therefore, be used as a 
single parameter to determine the type of P-lactamases. The results of lEF are therefore 
compared with the results of PCR detection of p-lactamase genes. 
Only two out of the 140 imipenem-resistant strains produced positive results in 
the detection of blamv, bla糧,b/asm,办blacrx, blasHV, and blaoxA p-lactamase 
genes by PCR. One isolate was shown to harbour the blaoxA-s gene by DNA sequencing 
of the amplicon obtained after PCR using primers specific for this gene. A P-lactamase of 
pi 7.6 instead of 7.1, the pi value of OXA-3 p-lactamase (http://www.lahev.org/studies), 
was produced by this isolate. Whether the P-lactamase with a pi of 7.6 was an AmpC 
enzyme, OXA-19, SHV-1, SHV-2, SHV-2A, SHV-6 OR SHV-7, or even OXA-5 (pl= 
7.62), OXA-7 (pl= 7.65) or OXA-6 (pl= 7.68) instead of an OXA-3 enzyme requires 
further investigation. The other isolate was shown to harbour the blaoxA-io gene but the P_ 
lactamase produced failed to show a band on the lEF gel. PCR is only able to detect the 
presence of p-lactamase genes but not the expression level of the corresponding protein. 
The expression level of OXA-3 and OXA-10 enzymes produced by the strains might be 
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not high enough to be detected by the lEF. The blaoxAs and hlaoxA-io are genes encoding 
class D extended spectrum P-lactamases (Bonnet, 2004). These are interesting findings as 
OXA-type P-lactamases are commonly found in P aeruginosa while they are rare in our 
isolates. Also, TEM-type, SHV-type, CTX-M-type and OXA-type enzyme, were 
produced by only two of them. The resistance to the extended-spectrum P-lactams in 
these imipenem-resistant strains was probably due to other mechanisms. 
It has long been recognized that AmpC P-lactamase is produced at low levels in P. 
aeruginosa and its production is induced by certain p-lactams particularly cefoxitin and 
imipenem. Such induction of AmpC p-lactamase production will lead to resistance to all 
penicillins and cephalosporins. Imipenem is considerably stable to AmpC hydrolysis and 
hyperproduction of AmpC enzyme is always found to interplay with other mechanisms, 
such as loss of porin and overexpression of efflux pump system to cause imipenem 
resistance (Giwercman, et al., 1990; Wu and Livermore, 1990). Hyperproduction of 
AmpC P-lactamase due to mutation in the regulatory gene ampD, ampG and ampR is 
commonly detected in imipenem-resistant P. aeruginosa (Lindberg, et al, 1987; Hanson 
and Sanders, 1999; Kuga et al., 2000). AmpC enzyme, OXA-19, SHV-6 and SHV-7 are 
not inhibited by clavulanic acid (Bush et al, 1995). The MICs of ticarcillin in the 
presence of clavulanic acid for our strains that produced P-lactamases of pis 7.6-8.2 were 
comparable to those of ticarcillin in the absence of clavulanic acid. Whether these strains 
overproduced AmpC and whether they overexpressed the oprD gene and together with 
other mechanisms resulted in imipenem resistance will be discussed later. 
P-Lactamases from all the 140 imipenem-resistant strains tested were shown by a 
bioassay method to be unable to hydrolyze imipenem. It has been shown that GIM-1, a 
MBL, has a catalytic efficiency that is much lower than that of other MBLs such as IMP-
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1, VIM-1, VIM-2, and SPM-1 (Laraki et al, 1999; Docquier et al, 2003; Murphy et al, 
2003; Castanheira et al, 2004). Thus, whether our strains produced MBLs with weak 
imipenem hydrolytic activity that could not be detected by the bioassay that we used 
should be investigated further by P-lactamase kinetics studies (Lorian，1995). 
3.2 Outer membrane permeability 
It has been shown that the outer membrane protein OprD is specific for the entry of 
carbapenems into bacterial cells and imipenem resistance is usually associated with OprD 
loss (Livermore, 1992; Huang and Hancock, 1993; Kohler et al, 1999). In this study, 
SDS-PAGE of outer membrane proteins extracted from 28 tested isolates showed that a 
� 4 6 kDa protein was present in only 20 isolates. Nine out of these 28 isolates were shown 
to have reduced oprD expression by real-time RT-PCR since their normalized expression 
relative to P. aeruginosa ATCC 27853 were less than 1. One of these isolates had an 
imipenem MIC of 128 mg/L and two with 64 mg/L. The mode and median MIC of 
imipenem were 32 mg/L for isolates with reduced oprD expression while they were 16 
mg/L for isolates had reduced oprD expression. These findings suggest that loss of outer 
membrane protein OprD occurred more often in strains with high resistance to imipenem 
than strains with low to intermediate resistance to imipenem in our study. 
Nineteen isolates showed an increase in oprD gene expression. However, the 46 
kDa OprD-like protein was absent in two isolates although their oprD expression was 
4.86 and 1.07 fold respectively. This was probably due to a disruption in translation from 
mRNA to tRNA and resulting in absence of the OprD protein (Koneman et al., 1997). In 
contrast, the oprD expression was 0.49-fold for one isolate but a band corresponding to 
that of the OprD protein was visible on the gel after SDS-PAGE. However, in most of the 
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previous studies reported, an OprD-like protein is not detected on the SDS-PAGE gel for 
the strains with decreased expression of oprD gene (Quale et al., 2006). 
Thus, OprD loss due to reduced oprD expression in the nine isolates was probably 
responsible for imipenem resistance. However, this might not be the sole mechanism. 
Firstly, the OprD protein is a specific channel for imipenem but not other P-lactams, 
including meropenem (Huang and Hancock，1993). Studies have shown that organisms 
which lost the OprD had an MIC of meropenem four-fold lower than that of imipenem 
(Livermore, 1992; Kohler et al., 1999). However, only two of our nine isolates had MICs 
of meropenem four-fold lower than that of imipenem while the rest had MICs of 
meropenem that were either the same (in one isolate) or >2-fold higher than those of 
imipenem. In addition, five of these nine isolates were resistant to four to 11 p-lactams 
other than imipenem while four were resistant to 12. Secondly, strains with loss of OprD 
but without other resistance mechanisms usually only exhibited a relatively low-level 
resistance (4 mg/L to 16 mg/L) to imipenem (Pai et al, 2001). 
Whether overproduction of AmpC enzyme contributed to imipenem resistance in 
these strains requires further investigation. Pai et al (2001) showed that strains with loss 
of the OprD protein as well as AmpC overproduction are resistant to imipenem and other 
p-lactams. 
3.3 Effects of regulatory gene mutations 
All 28 isolates that were selected for further investigation of membrane 
permeability were shown to possess a Leu26->Val substitution in the MexT regulatory 
protein. However, this substitution probably does not affect MexT function (Maseda et 
a/., 2000). Three other substitutions, namely Glu3i->Lys, Valuo—Phe and S e r n s ^ T h r 
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detected in five isolates have not been reported previously. The role of these substitutions 
in affecting the function of the MexT protein requires further investigation. 
The mexT gene could not be amplified in one isolate, and the second half of the 
mexTgQnt could not be amplified in 19 isolates, suggesting major mutations were present 
in the non-amplifiable region. Besides, oprD expression was reduced in four of the 
isolates. The mexT gene is a negative regulator for the expression of oprD and mutations 
can convert it from nonfunctional to functional (Kohler et al, 1999; Ochs et al, 1999; 
Maseda, et al, 2004). However, some of the isolates with a nonfunctional mexT gene had 
down-regulated the expression of oprD, suggesting that other factors were also involved. 
This finding has also been reported by Quale et al (2006). In another study, a newly 
described regulator mexS has been proposed to function as a putative negative regulator 
for OprD protein (Kohler et cd., 1999; Maseda et al., 2000b). 
The mexT gene, on the other hand, is reported as the positive regulator of the 
MexEF-OprN system which is responsible for the export of antibiotics such as 
fluoroquinolones, trimethoprim and chloramphenicol (Kohler et al, 1997; Kohler et al, 
1999； Maseda et al, 2000b). The mexEF-oprN is overexpressed in the nfic-C-iypQ 
mutants of P. aeruginosa, which are resistant to quinolones, imipenem, and 
choramphenicol (Kohler et al, 1997). The nfxC-iy^Q mutants are also cross-resistant to 
imipenem since the isolates also have decreased expression of OprD (Aubert et al, 1992; 
Fukuda et al, 1995; Masuda et al, 1995). The MexEF-OprN system was suspected to be 
overexpressed in nine isolates with a functional mexT gene. However, the correlation 
between overexpression of MexEF-OprN and decreased expression of OprD protein 
could not be drawn since other factors could be involved in regulating the oprD gene in 
the isolates. 
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4 Integrons in imipenem-resistant P. aeruginosa 
A class 1 integron was detected in >60% of our imipenem-resistant isolates. This 
integron is also commonly found in imipenem-resistant P. aeruginosa isolates around the 
world (Walsh et al, 2005). Genes coding for imipenem-hydrolyzing p-lactamases 
including IMP- and VIM-type have been reported to be present on class 1 integrons 
(Walsh et al, 2005). It is not surprising that we did not detect class 2 integrons in any of 
our isolates studied since they are much more uncommon than class 1 integrons (Hall and 
Collis，1995). 
Gene cassettes were detected in the majority of our integron-positive isolates 
(79%). The non-amplifiable gene cassettes in the isolates are probably due to the loss of 
3'-conserved segments {qacEM and sull). Absence of the 3'-conserved segment has been 
reported (Naas et al, 1998; Rosser and Young, 1999). It is interesting to note that all 
isolates shown to produce a MBL by the imipenem-EDTA disk method were positive for 
class 1 integron but 16 had lost the 3' conserved region. However, the 3' conserved 
region was detected in 95% of those isolates that were integron-positive and shown not 
to produce MBL by the same method. The difference between the two was statistically 
significant (p<0.05). It is possible that the majority of these MBL-producing strains had a 
major mutation in the 3' conserved region. 
No resistance genes were detected in the gene cassettes of >50% of the integron-
positive isolates. The blaoxA-3 and blaoxA-io genes, present in two of the isolates, were 
present on gene cassettes of a class 1 integron. The aadAl, aadA2 and aadA6 genes, 
detected in some of our integron-positive isolates, code for adenylytransferases that lead 
to resistance to streptomycin and spectinomycin (Shaw et al, 1993). Since we did not test 
the susceptibility of our isolates to these two aminoglycosides that are infrequently used 
for treatment of P. aeurginosa infections, the effect of the presence of these genes on 
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aminoglycoside susceptibility could not be determined. However, it is not surprising to 
find these aadA genes in gene cassettes in our isolates since they have been reported 
previously (Hall and Collis, 1995; Recchia and Hall, 1995). Other than these, no other 
resistance genes were detected in our isolates. 
5 Conclusions 
Imipenem-resistant R aerugniosa strains were commonly isolated from 
specimens from the respiratory tract, urinary tract and wounds of patients who were 
mainly elderly males. 
Of the 140 imipenem-resistant P. aeruginosa isolates studied, >50% were 
resistant to ten to 19 antibiotics. The majority produced a variety of p-lactamases while 
one each produced the OXA-3 and OXA-10 enzyme. Twenty were shown by a bioassay 
to produce MBL but common MBL genes including blamv, bla糧’ bla^xu were not 
detected in them. Crude P-lactamase extracts from these isolates were unable to 
hydrolyze imipenem. Reduced expression of the oprD gene was detected in nine out of 
the 28 isolates that were selected for further study of the mechanisms of imipenem-
resistance. Although mutations that converted 廳 x T regulator gene from nonfunctional to 
functional were detected in strains with decreased expression of the oprD gene, other 
factors were probably also responsible in regulating the expression of this gene. 
A class 1 integron was detected in the majority of isolates. The bhoxA-3, blaoxA-io, 
aadAl, aadA2 and aadA6 genes were present in gene cassettes of the integrons. The 3' 
conserved region could be absent in isolates that produced a MBL. 
6 Areas for further study 
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Although results from the present study have elucidated some of the mechanisms 
of imipenem-resistance in our P. aeurginosa isolates, several questions remain 
unanswered and investigations to elucidate them are worth pursuing: 
1. Production of carbapenemases is one of the mechanisms of imipenem 
resistance, however, it was detected in only a minority of our isolates. Besides, 
we were unable to characterize the carbapenemases other than to detect them 
using a phenotypic method. Whether these isolates produced novel MBL(s) 
should be investigated by kinetic studies and the encoding genes by molecular 
cloning. 
2. The AmpC enzyme is proposed to be overproduced in our strains. Whether 
overexpression of AmpC is responsible for imipenem-resistance should be 
studied by characterizing mutations leading to AmpC hyperproduction. 
3. Most of our imipenem resistant strains were simultaneously resistant to other 
classes of antibiotics. We have shown that the OprD protein was absent in 
some of these isolates, thus leading to imipenem-resistance. Whether the 
mexEF-oprN gene was also overexpressed causing these strains to be resistant 
to other antibiotics can be elucidated by performing real-time RT-PCR on the 
mexE gene. 
4. Whether the imipenem-resistant P. aeruginosa strains were progenies of a 
single or limited number of clones should be investigated by molecular typing 
using methods such as pulsed-field gel electrophoresis (PFGE) or PGR. 
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Figure 1.3. Structure of carbapenem and its derivate imipenem. 
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Figure 1.4. Efflux pump system of Gram-negative bacteria 
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Figure 1.5. Schematic representation of expression of mexEF-oprN and oprD genes 
regulated by mexT gene 
^^^^^^^^ ^ — _ — � [ m i l ： ： — X 
• 
：High-level expression 
： Very low-level expression 
) C : No expression or no function 
Mutations covert mexT^vom nonfunctional to functional and lead to down-regulate the 
expression oprD and up-regulate the expression of mexEF-oprN. 
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Figure 1.6. Schematic representation of class 1 integron 
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Figure 3.1. Phenotypic detection of non-MBL and MBL producing strains 
10 jig imipenem 
m 
^ ^ ^ ^ ^ ^ ^ H l O ^g imipenem + 750 ug EDTA 
^ o n - M B L producing strain with increased inhibition zone size 2 mm 
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I: f'. • 
m ： i 纏 
• H ^ ^ H ^ I 10 jag imipenem + 750 ug EDTA 
I MBL producing strain with increased inhibition zone size 12 mm 
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Figure 3.2. Bioassay to test the ability of p-lactamases to hydrolyse imipenem 
Distilled water in combination of imipenem (0.5 mg/L) 
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Figure 3.3. Agarose gel electrophoresis of PCR products for blaoxAS and blaoxA-io 
obtained after amplification using primers specific for OXA group I and OXA group II 
2 3 
1,353 bp路 H H ^ ^ I ^ H ^ ^ ^ B 
1,078 bp 
872 bp— P ^ ^ H H ^ ^ ^ ^ B 
603 bp ^ 
Lane 1: The size marker, OX 174 XMKIHae III marker 
Lane 2: 760-amplicons of blaoxA-w from isolate 2244 
Lane 3: 700-amplicions of blaoxA-s from isolate 4638 
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Figure 3.4. PCR products of aadAl, aadA2 and (5 obtained after amplification using 
primers for gene cassettes 
1 2 3 4 5 6 
1,000 ~ • ^ ^ ^ ^ I ^ L f l i ^ H 
850 _ 
650 ~ ^ 
500 ^ 
400 ——• 
300 _ ^ 
Lane 1: 1 kb plus DNA ladder 
Lane 2: 800-bp amplicons of aadAl 
Lane 3: 800-bp amplicons of aadA6 
Lane 4: 1,000 amplicons of aadA2 
Lane 5: 900 amplicons of aadA6 
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Figure 3.5. Structure of integrons 
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Figure 3.5 (Continued). 
5. 
IntI 碰 qacEM sull 
^ ^/vJ [/ 
aadA2 59be 
6. 
IntI 磁 qacEM sull 
aadA6 ^^^^ 
(1) Class 1 integrase. (2) Class 1 integron gene cassette. (3) Class 1 integron gene 
cassette encoding blaoxAS- (4) Class 1 integron gene cassette encoding blaoxA-w. (5) Class 
1 integron gene cassette encoding aadAL (6) Class 1 integron gene cassette encoding 
aadA2. (!) Class 1 integron gene cassette encoding aadA6. 
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Figure 3.6. SDS-PAGE of outer membrane proteins (OMPs) 
1 2 3 4 5 6 7 8 9 kDa 
�^a'MMM： iifiiinrfinii ini I f ''^^•••^•H'''' 
) “ , 響 B p ^ 
、 ： : ― … 物 ^ ^ ^ ^ ^ ^ 75,000 
議 : _ i i l _ .::續_;::: ： ： ： . . 丨 : , ” ” � : 丨 ： 
—^  g H H ^ 50,000 
等〜氣‘ • 暴 H H P 
‘ . • 、 - k 7 ¥御冊 � 4 6 k D a i 
丨， H P ^ 37,000 
^m 丨 售 
‘ • ^ ^ 25,000 
、…狐“ 
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2 Isolate no. 455 Yes 
3 Isolate no. 88 Yes 
4 ATCC 27853 Yes 
5 Isolate no. 2860 No 
6 Protein markers (Prestained SDS-PAGE standards broad range) 
7 Isolate no. 1287 Yes 
8 Isolate no. 4397 Yes 
9 Isolate no. 1122 Yes 
1 The size of OpD protein is - 4 6 kDa 
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Amikacin Sigma, MO, USA 
Gentamicin Sigma 
Netilmicin Schering Corporation, Bloomfield, USA 










Cefepime Bristol-Myers Squibb Co., NY , USA 
Aztreonam Bristol-Myers Squibb Co. 
Imipenem Merck, VA, USA 






Imipenem (10 fig) Oxoid, Hampshire, England 
Sources 
Media 
Luria-Bertani (LB) broth Difco Laboratories, MI, USA 
Mueller-Hinton (MH) Oxoid 
Nutrient agar Oxoid 
Markers 
(bXlAIHae III digest Amersham Pharmacia Biotech, Upsala, Sweden 
SDS-PAGE molecular weight 
standard (low range) Bio-Rad, CA, USA 
Kits 
API20E system BioMerieux, RCS Lyon, France 
Bio-Rad BCATM Protein Assay Bio-Rad 
MicroSpin S-300 HR columns Amersham Pharmacia Biotech 
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RNeasy Mini kit Qiagen, CA, USA 
TaqMan EZ RT-PCR Core 
Reagents kit Applied Biosystem, New Jersey, USA 
Chemical 
Acetic acid Merck 
BBL oxidase Becton Dickson & Co., MD, USA 
p-Mercaptoethanol Merck 
Bromophenol blue BDH Chemicals Ltd., Poole, UK 
Ethylenediamine tetraacetic acid 
(EDTA) Amersham Pharmacia Biotech 
Ethidium bromide Sigma, Missouri, USA 
Glycerol Merck 
Hydrochloric acid Sigma 
Lysozyme Sigma 
Methanol Merck 
Nitrocefm GlaxoSmith Kline 
Oxidase reagent Oxoid 
Phosphoric acid Merck 
Sodium carbonate Sigma 
Sodium chloride BDH 
Sodium hydroxide Merck 
Sodium phosphate Merck 
Tris-borate Merck 
Triton-100 USB, Cleveland, USA 
Gels 
Seakem®LE agarose Amersharm Pharmacia Biotech 
CriterionTM XT precast gel Bio-Rad 
Precast polyacrylamide pH 3 to 10 
gel Novel Experimental Technology, San Diego, USA 
Instruments 
ABI Prism � 7700 Sequence 
Detection Sytem Applied Biosystem 
Automatic inoculator MIC-2000 Dynatech, Virginia, USA 
Centrikon T-2080 centrifuge Kontron Instruments, Basel, Switzerland 
Chemidoc XRS Bio-Rad 
Eppendorf centrifuge Eppendorf AG, Hamburg, Germany 
Gel documentation system Amersham Pharmacia Biotech 
GNA 100 electrophoresis 
apparatus Amersham Pharmacia Biotech 
Multiskan ascent Thermo Electron Corporation, Waltham, MA, USA 
Multiphor II electrophoresis unit Amersham Pharmacia Biotech 
MultiTemp II thermostatic 
circulator Amersham Pharmacia Biotech 
PowerPac HCTM Bio-Rad 83 
NanoDrop ND-1000 NanoDrop Technologies, Inc, Wilmington, DE, USA 
Thermol controller (Gene Amp 
PCR system 9600) Perkin Elmer, Boston, USA 
Software 
Chromas 1.42 software Brisbane, Queensland, Australia 
ND-1000 3.3.0 NanoDrop Technologies 
Quantity One Bio-Rad 
Sequence Detection System 
software version 1.7. Applied Biosystem 
SDS-PAGE reagents 
20X XT-reducing agent Bio-Rad 
4X XT-sample buffer Bio-Rad 
20X XT MOPS running buffer Bio-Rad 
Coomassie blue G-250 Bio-Rad 
SDS-PAGE molecular weight 
standard (low range) Bio-Rad 
Real-time RT-PCR reagent 
Dnase I Progema, Madision, USA 
Recombinant RNasin® 
Ribonuclease inhibitor Progema 
RNase-free water Invitrogen 
RNase-free 25 mM EDTA Progema 
PCR reagents 
lOX Taq Buffer Amersham Pharmacia Biotech 
DNA polymerization mix Amersham Pharmacia Biotech 
Primers Invitrogen, CA, USA 
Taq DNA polymerase Amersham Pharmacia Biotech 
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Table 2.2. Solvents used for dissolving the antibiotics and concentration range of 
antibiotics tested 
Concentration range 
Antibiotics Solvent (mg/L) 
Aminoglysides-
Amikacin Distilled water 0.5-256 
Gentamicin Distilled water 0.06-128 
Netilmicin Distilled water 0.12-256 
Tobramycin Distilled water 0.06-128 
P-lactams-
Piperacillin Distilled water 2-1024 
Piperacillin/ 2/2-1024/2 
tazobactam Distilled water 
Ticarcillin Distilled water 2-1024 
Ticarcillin/ 2/2-1024/2 
clavulanic acid Distilled water 
Cefoxitin Distilled water 0.5-256 
Cefotaxime Distilled water 0.25-512 
Ceftazidime Saturated sodium carbonate 0.12-256 
Ceftriaxone 0.2% sodium carbonate 0.12-256 
Cefepime O.IM phosphate buffer, pH 6.0 0.06-128 
Aztreonam Saturated sodium carbonate 0.06-128 
Imipenem 0.0IM phosphate buffer, pH 7.0 0.06-128 
Meropenem Distilled water 0.06-128 
Fluoroquinolones-
Levofloxacin O.IN sodium hydroxide 0.06-128 
Norfloxacin O.IN sodium hydroxide 0.06-128 
Ofloxacin O.IN sodium hydroxide 0.06-128 
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Table 2.3. C o m p o n e n t s of P C R for hla\u?, bla、抛,bla^m, bla-xEu, blacjx, blasm, and 
blaoxA 
Stock Volume (|LI1) Final 
Reagent concentration concentration 
Forward primers 25 |LIM 0.5 0.5 [xM 
Reverse primers 25 |.iM 0.5 0.5 ^iM 
dNTPs 10 mM 0.5 0.2 mM 
lOX Tag buffer 10 X 2.5 I X 
Taq DNA polymerase 1 U/jiil 0.2 0.2 U 
DNA template 1 -
Nuclease free water 19.55 
Total 25 
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Table 2.5. Components of PCR for intll and intI2 
Stock Volume (]LI1) Final 
Reagent concentration concentration 
Forward primers 25 | iM 0.5 0.5 iliM 
Reverse primers 25 | iM 0.5 0.5 |LIM 
dNTPs 10 mM 0.5 0.2 mM 
lOX Taq buffer 10 X 2.5 I X 
Taq DNA polymerase 1 U/iul 0.2 0.2 U 
DNA template 1 -
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Table 2.9. Components of PCR for 3'-conserved segments 
Stock Volume (jul) Final 
Reagent concentration concentration 
Forward primers 25 [iM 0.5 0.5 luM 
Reverse primers 25 [ M 0.5 0.5 |aM 
dNTPs 10 mM 0.5 0.2 mM 
lOX Taq buffer 10 X 2.5 I X 
Tag DNA polymerase 1 U/|il 0.5 0.5 U 
DNA template 1 -
Nuclease-free water 19.5 
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Table 2.9. Components of PCR for 3'-conserved segments 
Stock Volume ( ^ i l ) F i n a l 
Reagent concentration concentration 
Forward primers 25 |LIM 0.5 0.5 |LIM 
Reverse primers 25 |LIM 0.5 0.5 [iM 
dNTPs 10 mM 0.5 0.2 mM 
lOX Taq buffer 10 X 2.5 I X 
Taq DNA polymerase 1 U/^il 0.2 0.2 U 
DNA template 1 -
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Table 2.11. Components of real-time RT-PCR for oprD and rpoD 
Stock Volume (|il) 
Reagent concentration Final concentration 
TaqMan EZ buffer 5 5 f x 
Manganese acetate 25 mM 3 3 mM 
dATP 10 mM 0.75 0.3 mM 
dCTP 10 mM 0.75 0.3 mM 
dGTP 10 mM 0.75 0.3 mM 
dUTP 20 mM 0.75 0.6 mM 
Forward primer 100 jiM 0.225 0.3 |LIM 
R e v e r s e p r i m e r 100 |LIM 0 . 2 2 5 0 . 3 ^ M 
Probe 10 ^iM 0.625 0.2 |LIM 
AmpErase UNG 1 U/|al 0.25 0.25 U 
rTth DNA polymerase 2.5 U/|al 1 0.5 U 
Total 25 
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Table 2 . 9 . Components of PCR for 3'-conserved segments 
Stock Volume ( [ i \ ) F i n a l 
Reagent concentration concentration 
Forward primers 25 JUM 0.5 0.5 |LIM 
Reverse primers 25 |LIM 0.5 0.5 |iM 
dNTPs 10 mM 0.5 0.2 mM 
lOX Taq buffer lOX 2.5 I X 
Taq DNA polymerase 1 U/|al 0.2 0.2 U 
DNA template 1 -
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Table 3.1. Prevalence of P. aeruginosa isolated from different patient specimens from 
January 2001 to May 2005 in the New Territories East Cluster hospitals 
% (no.) of isolates in different 
Specimen type specimens 
Sputum 32.1% (45) 
Bronchial and tracheal aspirate 30% (42) 
Urine 19.3% (27) 
Wound 12.1% (17) 
丨Others 6.4% (9) 
^Others include body fluid, pus and miscellaneous 
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Table 3.2. Age and sex distribution of patients 
No. of isolate from Total % (no.) 
Age Males Females 
0 - 9 2 0 1.4% (2) 
10 � 6 1 23 21 31.4% (44) 
61 � 7 5 33 9 30% (42) 
76 or above 40 12 37.1% (52) 
Total 98 42 
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Table 3.3. Antimicrobial susceptibilities of imipenem-resistant P. aeruginosa isolated from 
patients in hospitals of the New Territories East Cluster from January 2001 to May 2005 
MIC (mg/L) 
% of isolates 
resistant to breakpoint 
Year of concentrations in mg/L 
Antimicrobial agents isolation Range MIC50 MIC90 in brackets 
Aminoglyosides 
Amikacin 
2001 8 -32 16 16 7.7 (16) 
2002 4 � > 2 5 6 16 16 11.4 
2003 8-128 16 32 10.3 
2004 8 � 6 4 16 32 21.4 
2005 1-32 8 16 8 
Total 4 � � 2 5 6 16 32 11.8 
Gentamicin 
2001 1 � 8 4 8 31 (4) 
2002 0 . 2 5 � � 6 4 4 16 31.4 
2003 1 � > 6 4 4 16 28.2 
2004 <0.06-64 4 32 11 
2005 0 . 1 2 � 8 4 8 12 
Total <Q.06~>64 4 16 22.7 
Netilmicin 
2001 4 � 3 2 4 16 23 (8) 
2002 0 . 5 � > 1 2 8 8 32 25.7 
2003 4-128 8 16 20.5 
2004 2 � � 1 2 8 8 64 10.7 
2005 邻.25 〜>128 4 16 12 
Total <0.25->128 8 32 18.4 
Tobramycin 
2001 0.5>64 1 4 7.7(4) 
2002 0 . 1 2 � 6 4 1 4 8.6 
2003 0 . 5 � � 6 4 1 >64 10.3 
2004 0 . 1 2 � 6 4 1 2 7 
2005 0 . 2 5 � 2 1 2 0 
Total 0 . 1 2 � 6 4 1 4 6.7 
P-lactam 
Piperacillin 
2001 4-512 32 256 15.4(64) 
100 
Table 3.3 (Continued). 
MIC (mg/L) 
% of isolates 
resistant to breakpoint 
Year of concentrations in mg/L 
Antimicrobial agents isolation Range MIC50 MIC90 in brackets 
Piperacillin 2 -256 ^ ^ ^ 
2003 4-512 32 256 25.6 
2004 4-512 32 512 28.6 
2005 <2-1024 64 512 40 
Total <2-1024 32 256 27.1 
P iperac illi n/tazobactam 
2001 4-256 64 256 15.4(64) 
2002 4-512 32 256 20 
2003 4-512 32 256 20.5 
2004 4-256 32 64 25 
2005 4-256 64 256 36 
Total 4 -256 32 256 23.4 
Ticarcillin 
2001 3 2 � 5 1 2 128 256 53.8 (64) 
2002 16�>1024 128 512 60 
2003 1 6 � 5 1 2 128 256 51.3 
2004 4-512 64 512 57.1 
2005 4-512 128 256 56 
Total 4 � > 1 0 2 4 128 256 55.6 
Ticarcillin/clavulanic 
acid 
2001 1 6 � 5 1 2 64 256 46.2(64) 
2002 16�>1024 64 512 40 
2003 1 6 � 5 1 2 128 256 51.3 
2004 2-512 64 256 42.9 
2005 2-512 128 512 56 
Total 2 � > 1 0 2 4 64 256 47.3 
Cefoxitin 
2001 >256 >256 >256 100(16) 
2002 >256 >256 >256 100 
2003 1 6 � > 2 5 6 >256 >256 97.4 
2004 >256 >256 >256 100 
2005 >256 >256 >256 100 
Total 16 � � 2 5 6 >256 >256 99.5 
Cefotaxime 
2001 16�>128 >128 >128 100 (8) 
2002 8 � � 1 2 8 64 >128 97.1 
101 
Table 3.3 (Continued). 
MIC (mg/L) 
% of isolates 
resistant to breakpoint 
Year of concentrations in mg/L 
Antimicrobial agents isolation Range MIC50 MIC90 in brackets 
Cefotaxime i m 8 � > 1 2 8 128 > m ^ 
2004 4 � > 1 2 8 128 >128 96.4 
2005 4 � > 1 2 8 128 >128 96 
Total 4 � > 1 2 8 128 >128 96.7 
Ceftazidime 
2001 0 . 5 � 1 2 8 32 64 61.5 (8) 
2002 1-128 4 128 31.4 
2003 1 � 1 2 8 8 64 48.7 
2004 0 .5�>128 8 32 42.9 
2005 0 .5�>128 8 128 44 
Total 0.5 � > 1 2 8 8 128 45.7 
Ceftriaxone 
2001 3 2 � � 1 2 8 >128 >128 100 (8) 
2002 16�>128 128 >128 100 
2003 8 � > 1 2 8 >128 >128 94.8 
2004 4 � > 1 2 8 >128 >128 96.4 
2005 4 � > 1 2 8 >128 >128 96 
Total 4 � > 1 2 8 >128 >128 97.4 
Cefepime 
2001 4-128 16 64 69.2 (8) 
2002 4-128 16 64 65.7 
2003 4-128 16 32 64.1 
2004 4 � 6 4 16 32 60.7 
2005 2 � > 1 2 8 16 64 80 
Total 2 � > 1 2 8 16 64 67.9 
Aztreonam 
2001 8-128 32 128 69.2 (8) 
2002 4 � > 1 2 8 16 128 60 
2003 4 � > 1 2 8 16 128 64.1 
2004 1-128 16 128 53.6 
2005 0 .12�128 16 64 68 
Total 0.12 � 1 2 8 16 128 63 
Imipenem 
2001 8-32 16 32 100 (4) 
2002 8-128 16 32 100 
2003 8-64 16 32 100 
2004 8-32 8 16 100 
2005 8-32 8 16 100 
102 
Table 3.3 (Continued). 
MIC (mg/L) 
% of isolates 
resistant to breakpoint 
Year of concentrations in mg/L 
Antimicrobial agents isolation Range MIC50 MIC90 in brackets 
Imipenem Total 8 -128 16 32 100 
Meropenem 
2001 4-128 16 >128 76.9(4) 
2002 1 � > 1 2 8 16 >128 74.3 
2003 4 � > 1 2 8 16 >128 76.9 
2004 1 � > 1 2 8 8 64 75 
2005 1 � > 1 2 8 32 >128 88 
Total 1 � � 1 2 8 16 >128 78.2 
Fluoroquinolones 
Levofloxacin 
2001 0 . 2 5 � 8 2 8 7.7 (4) 
2002 如 2 〜64 1 4 5.7 
2003 0.25-64 1 8 15.4 
2004 0 . 2 5 � > 6 4 2 8 17.8 
2005 0 . 2 5 � > 6 4 1 8 20 
Total 邻 .12 � > 6 4 1 8 133 
Norfloxacin 
2001 0.5-8 1 8 15.4 (4) 
2002 0 . 5 � > 6 4 1 8 11.4 
2003 0 . 5 � � 6 4 1 8 12.8 
2004 0 . 5 � > 6 4 1 32 21.4 
2005 0 . 5 � > 6 4 1 32 16 
Total 0.5 � � 6 4 1 8 
Ofloxacin 
2001 0 . 5 � 3 2 1 16 30.8 (2) 
2002 0 . 2 5 � > 3 2 1 4 14.3 
2003 1~>32 2 16 30.8 
2004 0.25〜>32 1 >32 32.1 
2005 0 . 5 � � 3 2 2 >32 32 
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Table 3.5. Results of phenotypic detection of MBL producing strains 
No. of strains 
with MICs of 
IMpi (mg/L) 
Increased zone Total no. of 
diameters (mm) strains 8 16 32 64 128 
"2 i i 0 0 0 0 
3 12 7 4 1 0 0 
4 33 16 16 1 0 0 
5 35 16 15 3 1 0 
6 25 6 17 8 0 0 
_7 U 3 7 4 0 0 
8 8 2 1 3 1 0 
9 4 0 1 2 0 1 
10 3 0 1 2 0 0 
11 1 0 0 1 0 0 




Table 3.6. The isoelectric points of P-lactamases produced by the isolates 
% of isolates 
Total no. of pi values pi values (no.) 
1 T e 8.8 (8) 
7.7 8.8 (8) 
7.8 15.4(14) 




Total (7) 75.8 (69) 




8.0,8.1 2.2 (2) 
Total (5) 6.6 (6) 
3 7.6,7.8,8.0 1.1 (1) 
7.7, 7.9, 8.0 2.2 (2) 
7.7,8.0,8.1 1.1 (1) 
7.8,8.0,8.2 1.1 (1) 
7.9, 8.1,8.2 2.2 (2) 
8.0, 8.1,8.2 2.2 (2) 
Total (6) 9.9 (9) 
4 7.6, 7.8, 8.0, 8.2 2.2 (2) 
7.7, 7.9, 8.0, 8.2 2.2 (2) 
7.8, 7.9, 8.0, 8.2 3.3 (3) 
Total (3) 7.7 (7) 
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Table 3.9. Distribution of resistance genes in gene cassettes 
Resistant gene No of isolates with amplicon size in bp Total % (no.) 
800 900 ^ 
aadAl 3 0 0 4 ( 3 ) 
aadA2 0 1 27 70 (28) 
aadA6 1 3 3 9 (7) 
blaoxA-3 0 0 1 1 (1) 
blaoxA-io 0 0 1 1(1) 
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C T A C C T C T C A C T A G T G A G G G G C G G C A G C G C A T C A A G C G G T G A G C G C A C T C C G G 
C A C C G C C A A C T T T C A G C A C A T G C G T G T A A A T C A T C G T C G T A G A G A C G T C G G A A 
T G G C C G A G C A G A T C C T G C A C G G T T C G A A T G T C G T A A C C G C T G C G G A G C A A G G C 
C G T C G C G A A C G A G T G G C G G A G G G T G T G C G G T G T G G C G G G C T T C G T G A T G C C T G 
C T T G T T C T A C G G C A C G T T T G A A G G C G C G C T G A A A G G T C T G G T C A T A C A T G T G A T 
G G C G A C G C A C G A C A C C G C T C C G T G G A T C G G T C G A A T G C G T G T G C T G C G C A A A A 
A C C C A G A A C C A C G G C C A G G A A T G C C C G G C G C G C G G A T A C T T C C G C T C A A G G G C 
G T C G G G A A G C G C A A C G C C G C T G C G G C C C T C G G C C T G G T C C T T C A G C C A C C A T G 
C C C G T G C A C G C G A C A G C T G C T C G C G C A G G C T G G G T G C C A A G C T C T C G G G T A A C 
A T C A A G G C C C G A T C C T T G G A G C C C T T G C C C T C C C G C A C G A T G A T C G T G C C G T G A 
T C G A A A T C C A G A T C C T T G A C C C G C A G T T G C A A A C C C T C A C T G A T C C G C A T G C C C 
G T T C C A T A C A G A A G C T G G G C G A A C A A A C G A T G C T C G C C T T C C A G A A A A C C G A G 
G A T G C G A A C C A C T T C A T C C G G G G T C A G C A C C A C C G G C A A G C G C C G C G A C G G C C 
G A G G T C T T C C G A T C T C C T G A A G C C A G G G C A G A T C C G T G C A C A G C A C C T T G C C G 
T A G A A G A A C A G C A A G G C C G C C A A T G C C T G A C G A T G C G T G G A G A C C G A A A C C T 
T G C G C T C G T T C G C C A G C C A G G A C A G A A A T G C C T C G A C T T C G C T G C T G C C C A A G 
G T T G C C G G G T G A C G C A C A C C G T G G A A A C G G A T G A A G G C A C G A A C C C A G T G G A 
C A T A A G C C T G T T C G G T T C G T A A A C T G T A A T G C A A G T A G C G T A T G C G C T C A C G C 
A A C T G G T C C A G A A C C T T G A C C G A A C G C A G C G G T G G T A A C G G C G C A G T G G C G 
G T T T T C A T 
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T G A T G T T A T G G A G C A G C A A C G A T G T T A C G C A G C A G G G C A G T C G C C C T A A A A C A 
A A G T T A G A C A T C A T G A G G G T A G C G G T G A C C A T C G A A A T T T C G A A C C A A C T A T C 
A G A G G T G C T A A G C G T C A T T G A G C G C C A T C T G G A A T C A A C G T T G C T G G C C G T G C 
A T T T G T A C G G C T C C G C A G T G G A T G G C G G C C T G A A G C C A T A C A G C G A T A T T G A T 
T T G T T G G T T A C T G T G G C C G T A A A G C T T G A T G A A A C G A C G C G G C G A G C A T T G C T C 
A A T G A C C T T A T G G A G G C T T C G G C T T T C C C T G G C G A G A G C G A G A C G C T C C G C G C 
T A T A G A A G T C A C C C T T G T C G T G C A T G A C G A C A T C A T C C C G T G G C G T T A T C C G G C 
T A A G C G C G A G C T G C A A T T T G G A G A A T G G C A G C G C A A T G A C A T T C T T G C G G G T A 
T C T T C G A G C C A G C C A T G A T C G A C A T T G A T C T A G C T A T C C T G C T T A C A A A A G C A A 
G A G A A C A T A G C G T T G C C T T G G T A G G T C C G G C A G C G G A G G A A T T C T T T G A C C C G 
G T T C C T G A A C A G G A T C T A T T C G A G G C G C T G A G G G A A A C C T T G A A G C T A T G G A A 
C T C G C A G C C C G A C T G G G C C G G C G A T G A G C G A A A T G T A G T G C T T A C G T T G T C C C 
G C A T T T G G T A C A G C G C A A T A A C C G G C A A A A T C G C G C C G A A G G A T G T C G C T G C C 
G A C T G G G C A A T A A A A C G C C T A C C T G C C C A G T A T C A G C C C G T C T T A C T T G A A G C 
T A A G C A A G C T T A T C T G G G A C A A A A A G A A G A T C A C T T G G C C T C A C G C G C A G A T C 
A C T T G G A A G A A T T T A T T C G C T T T G T G A A A G G C G A G A T C A T C A A G T C A G T T G G T A 
A A T G A T G T C T A A C A A T T C G T T C A A G C C G A C C G C G C T A C G C G C G G C G G C T T A A C 
T C C G G C G T T 
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T G A T G T T A T G G A G C A G C A A C G A T G T T A C G C A G C A G G G C A G T C G C C C T A A A A C A 
A A G T T A G A C A T C A T G A G T A A C G C A G T A C C C G C C G A G A T T T C G G T A C A G C T A T C 
A C T G G C T C T C A A C G C C A T C G A G C G T C A T C T G G A A T C A A C G T T G C T G G C C G T G C 
A T T T G T A C G G C T C T G C A C T G G A C G G T G G C C T G A A G C C A T A C A G T G A T A T T G A T T 
T G C T G G T T A C T G T G G C T G C A C G G C T C G A T G A G A C T G T C C G A C A A G C C C T G G T C 
G T A G A T C T C T T G G A A A T T T C T G C C T C C C C T G G C C A A A G T G A A G C T C T C C G C G C C 
T T G G A A G T T A C C A T C G T C G T G C A T G G T G A T G T T G T C C C T T G G C G T T A T C C G G C C 
A G A C G G G A A C T G C A A T T C G G G G A G T G G C A G C G T A A G G A C A T T C T T G C G G G C A T 
C T T C G A G C C C G C C A C A A C C G A T G T T G A T C T G G C T A T T C T G C T A A C T A A A G T A A G 
G C A G C A T A G C C T T G C A T T G G C A G G T T C G G C C G C A G A G G A T T T C T T T A A C C C A G T 
T C C G G A A G G C G A T C T A T T C A A G G C A T T G A G C G A C A C T C T G A A A C T A T G G A A T T 
C G C A G C C G G A T T G G G A A G G C G A T G A G C G G A A T G T A G T G C T T A C C T T G T C T C G C 
A T T T G G T A C A G C G C A G C A A C C G G C A A G A T C G C A C C G A A G G A T A T C G T T G C C A A 
C T G G G C A A T G G A G C G T C T G C C A G A T C A A C A T A A G C C C G T A C T G C T T G A A G C C C 
G G C A G G C T T A T C T T G G A C A A G G A G A A G A T T G C T T G G C C T C A C G C G C G G A T C A G 
T T G G C G G C G T T C G T T C A C T T C G T G A A A C A T G A A G C C A C T A A A T T G C T T A G T G C C 
A T G C C A G T G A T G T C T A A C A A T T C A T T C A A G C C G A C G C C G C T T C G C G G C G C G G C 
T T A A T T C A G G C G T T A G T A C C A C T G A A A C C C T C C T T T A T T T C G C C C A T G T T T A T T C 
A A A C G G C A T T C A G T T T C T C A A A C G C T G T G C A G C G C T G G G T T T G C C G T T T C T C T G 
G G C T T C G C C T G G T G G C G T T A C G C T G G T T T G T G G T C T T T T T G G C C T C T G G C C C T T G 
T G T A G C A A G C G C G A G C A G C T A T T T T T T T C G T A G T G C T G T G C C G C C T C G G T G G C A 
C C G T G C C T T T T C G C A G T T A G C G C C C G T C G C C A A G T T A C G G T T A T C C G T T T T G G C 
T T C T G G C T C T A A C A T T T C G G T C A A G C C G A C C C G C A T T C T G C G G T C G G C 
T T A A C T C G C C C G T T A G A T G C A 
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G G C C A G T T C G A A G C C G A G A C C G G A C G G C A G C G C A G C C T G C T C G G G G G C C A G G 
T T C T G A C G C C A G A G C A C A T C C T T C C A G C T C A C G C C G A T C G C C T G G A C A C G C A T C 
A G G A C T T C C C C T G C G G C C G G C G C C G G G G T C G G C A G C T C T T C G C A T T T G A G G A C 
C T C T G G C G G G C C A A A C T G A T G A A A A C G G A T C A C T C G G G A C A T C G C A A A C C T C T 
G C A G T G C A T C A C G G G G T G A A T A A C C T C A T G G G T T G T G A C T G T A T C C G C C C A T G 
C C T G A C A A A A C C A C C C G T C G T T A T T G A T A A T G G C T A T G C C T G T C A G T G A T C C T A 
T G C C C C T C C G G C A C C T C G C C A G G C C C C G C C C C G T C T C G C A C G C A A G G C T T G A C 
G G C G A G C C C C C G C G G T T G C A G C C T C T A G C C C C T G G A A A C G A G G A A A C G C C A T G 
A A C C G A A A C G A C C T G C G C C G C G T C G A T C T G A A C C T G C T G A T C G T G T T C G A G A C 
C C T G A T G C A C G A A C G C A G C C T G A C C C G C G C C G C A G A G A A A C T G T T C C T C G G C C 
A G C C G G C C A T C A G C G C C G C G C T G T C G C G C C T G C G C A C G C T G T T C G A C G A C C C G 
C T G T T C G T C C G T A C C G G A C G C A G C A T G G A G C C C A C C G C G C G A G C C C A G G A A A T 
C T T C G C C C A C C T G T C G C C G G C G C T G G A T T C C A T C T C C A C C G C C A T G A G T C G C G C 
C A G C G A G T T C G A T C C G G C G A C C A G C A C C G C G G T G T T C C G C A T C G G C C T T T C C G 
A C G A C G T C G A G T T C G G C C T G T T G C C G C C C C T G C T C C G C C G C C T G C G C G C G G A G 
G C G C C G G G G A T C G T C C T C G T C G T G C G C C G C G C C A A C T A T C T A T T G A T G C C G A A 
C C T G C T G G C C T C G G G G G A G A T C T C G G T G G G C G T C A G C T A C A C C G A C G A A C T G C 
C G G C C A A C G C C A A G C G C A A G A C C G T G C G C C G C A G C A A G C C G A A G A T C C T C C G 
C G C C G A C T C C G C G C C C G G C C A G C T G A C C C T C G A C G A C T A T T G C G C G C G A C C G C 
A C G C G C T G G T G T C C T T C G C C G G C G A C C T C A G C G G C T T C G T C G A C G A G G A G C T G 
G A A A A A T T C G G C C G C A A G C G C A A G G T G G T C C T G G C G G T G C C G C A G T T C A A C G G 
C C T C G G C A C C C T C C T G G C C G G C A C C G A C A T C A T C G C C A C C G T G C C C G A C T A C G 
C C G C C C A G G C G C T G A T C G C C G C C G G C G G C C T A C G C G C C G A G G A C C C A C C G T T C 
G A G A C C C G G G C C T T C G A A C T G T C G A T G G C T T G G C G C G G C G 
C C C A G G A C A A C G A T C C G G C C G A A C G C T G G C T G C G C T C G C G G A T C A G C A T G T T C 
A T C G G C G A T C C G G A C A G T C T C T G A G C C C T C C G G C A G C T A C C C G C A C G A G G C G T 
C G C A A C G G G A A A A T C G A T C G C G C G C C G C G G G T G T G C G G C T T A T T C C A T C G A A A 
G C A C T G T C C A T A A C C A T C G A C T G T T A C A G A A A A C G A A A A A C C A T 
G T A T C A C T G T T C G T G A T 
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